Toxicology – Amrinone (Inamrinone) and Milrinone

Core Concept

Amrinone, now generally called inamrinone, and milrinone are phosphodiesterase-3 (PDE3) inhibitors with combined:

• Positive inotropic effects – increase cardiac contractility
• Vasodilator effects – decrease systemic and pulmonary vascular resistance

For this reason they are sometimes called inodilators.

Milrinone has largely replaced inamrinone in contemporary clinical practice because of more favorable pharmacologic and adverse-effect characteristics.

The major acute toxic effects are:

Excessive vasodilation → hypotension

and

Increased myocardial excitability → tachyarrhythmias/ventricular dysrhythmias

There is no specific antidote.

Modern Clinical Role

Milrinone may be used for short-term hemodynamic support in selected patients with:

• Acute decompensated heart failure with low cardiac output
• Severe ventricular dysfunction
• Post-cardiac-surgery low-output states
• Selected right ventricular failure
• Selected pulmonary hypertension situations

Its use requires careful hemodynamic assessment because increased contractility may be offset by substantial vasodilation.

Inamrinone is now rarely used compared with milrinone.

PDE3 Physiology

Normally:

Adenylyl cyclase → cAMP

while:

PDE3 breaks down cAMP

PDE3 inhibition therefore increases intracellular cAMP.

Cardiac Mechanism

In cardiac myocytes:

PDE3 inhibition → ↑ cAMP → ↑ protein kinase A activity → ↑ intracellular Ca²⁺ availability → stronger contraction

The result is:

• Increased myocardial contractility
• Increased stroke volume
• Increased cardiac output in appropriately selected patients

Unlike catecholamines, the drug does not require direct β-receptor stimulation to generate its primary inotropic effect.

Vascular Mechanism

In vascular smooth muscle, increased cAMP promotes relaxation.

Therefore:

PDE3 inhibition → vasodilation → ↓ systemic vascular resistance

It can also decrease pulmonary vascular resistance.

Thus the overall pharmacologic profile is:

↑ Contractility + ↓ afterload = inodilation

Why Hypotension Occurs

The same vasodilating action that may improve forward cardiac output can become excessive.

In toxicity:

Excessive vasodilation → ↓ SVR → hypotension → impaired organ perfusion

This is especially important in patients who already have:

• Low blood pressure
• Volume depletion
• Severe heart failure
• Other vasodilating medications

Toxic Dose

A reliable universal toxic threshold has not been established.

Most clinically important toxicity historically occurred through:

• Therapeutic dosing errors
• Excessive IV administration
• Drug accumulation

Clinical severity is more useful than a reported amount.

Milrinone and Renal Function

Milrinone is substantially dependent on renal elimination.

Therefore:

Renal impairment → reduced clearance → prolonged exposure → greater risk of hypotension and dysrhythmias

Renal function is consequently an important consideration during both therapeutic use and suspected toxicity.

Dose accumulation may occur even without a single dramatic overdose.

Acute Cardiovascular Toxicity

The major findings are:

• Hypotension
• Tachycardia
• Palpitations
• Ventricular ectopy
• Supraventricular dysrhythmias
• Ventricular dysrhythmias

Severe hypotension can lead to:

• Altered mental status
• Myocardial ischemia
• Acute kidney injury
• Shock

Dysrhythmias

PDE3 inhibition can increase myocardial excitability.

Possible rhythm disturbances include:

• Premature ventricular complexes
• Atrial tachyarrhythmias
• Ventricular tachycardia
• Other ventricular dysrhythmias

Risk may be increased by:

• Hypokalemia
• Hypomagnesemia
• Structural heart disease
• Myocardial ischemia
• Other proarrhythmic medications

Electrolytes

Electrolyte abnormalities can increase dysrhythmia risk.

Particular attention should be given to:

• Potassium
• Magnesium
• Calcium

Hypokalemia may occur in patients receiving intensive heart-failure treatment, particularly when concurrent diuretics are being used.

Gastrointestinal Effects

Reported adverse effects include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort

These are generally less important than cardiovascular toxicity during acute poisoning.

Thrombocytopenia

Inamrinone has historically been associated with thrombocytopenia, particularly during sustained therapy.

It is generally:

• Dose/exposure related
• Reversible after dose reduction or discontinuation

This adverse effect was one factor limiting long-term use.

Milrinone has a substantially lower tendency to produce this complication.

Hepatic Effects

Inamrinone has also been associated with:

• Aminotransferase abnormalities
• Rare clinically significant hepatotoxicity

This is more relevant to prolonged exposure than a brief acute overdose.

Why Chronic Oral PDE3 Therapy Fell Out of Favor

An important modern point is that chronic oral PDE3 inhibitor therapy for heart failure did not improve long-term survival and was associated with adverse outcomes.

Therefore, contemporary milrinone use is primarily short-term IV therapy in selected patients, rather than routine chronic oral heart-failure treatment.

Diagnosis

Diagnosis is based primarily on:

• Medication history
• Infusion history
• Hemodynamic findings
• ECG
• Renal function
• Electrolytes

There is no routinely useful serum inamrinone or milrinone concentration for emergency toxicologic decision-making.

Essential Assessment

In clinically important toxicity, evaluate:

• Blood pressure
• Heart rate
• Mental status
• Peripheral perfusion
• ECG
• Continuous cardiac rhythm

Laboratory evaluation may include:

• Electrolytes
• Potassium
• Magnesium
• Calcium
• Creatinine
• Glucose

Additional tests depend on severity.

Chronic-Therapy Evaluation

If adverse effects develop during prolonged inamrinone exposure, additional evaluation can include:

• CBC with platelet count
• Liver enzymes
• Renal function
• Electrolytes

For milrinone, renal function is especially important because impaired clearance can substantially prolong its effects.

Initial Management of IV Overdose

The first step in excessive IV administration is straightforward:

Stop the infusion.

Then assess:

• Airway and breathing
• Blood pressure and perfusion
• Cardiac rhythm
• Renal function
• Electrolytes

Significant hypotension or dysrhythmia warrants monitored critical care.

Hypotension Management

Treatment depends on both volume status and cardiac function.

Appropriate isotonic crystalloid may be useful if the patient is volume depleted.

However, many patients receiving PDE3 inhibitors already have severe heart failure, so indiscriminate fluid loading may cause:

• Pulmonary edema
• Worsening congestion
• Respiratory compromise

Fluid therapy should therefore be individualized.

Trendelenburg – Modern Correction

Routine Trendelenburg positioning is obsolete as treatment for hypotension.

It does not provide reliable sustained improvement in organ perfusion and may worsen respiratory mechanics in some patients.

Vasopressors

Persistent vasodilatory hypotension may require a vasopressor.

A vasoconstricting agent such as norepinephrine is commonly appropriate when significant vasodilatory shock persists.

Selection should account for:

• Cardiac function
• Rhythm
• Degree of vasodilation
• Perfusion
• Other medications

Atropine

The historical source recommends atropine if hypotension is caused by bradycardia.

Atropine may be appropriate for clinically important symptomatic bradycardia, but bradycardia is not the characteristic toxicity of PDE3 inhibition.

Hypotension should not automatically be treated with atropine unless the heart-rate disturbance is actually contributing to poor perfusion.

Dysrhythmia Management

Management includes:

• Stop the offending drug
• Correct hypoxemia
• Correct significant potassium abnormalities
• Correct magnesium abnormalities
• Treat acid–base disturbances
• Evaluate myocardial ischemia
• Follow contemporary resuscitation principles for unstable dysrhythmias

Electrical cardioversion/defibrillation is used when indicated by the rhythm and hemodynamic state.

Drug Interactions

Concomitant medications may amplify toxicity.

Examples include:

• Other vasodilators → greater hypotension
• Other positive inotropes → greater myocardial oxygen demand or arrhythmia risk
• Diuretics → electrolyte depletion
• Other proarrhythmic drugs → greater dysrhythmia risk

Medication compatibility is also important for IV therapy; drugs should not be mixed in the same line unless compatibility is established.

Outflow Obstruction

Increasing contractility while reducing vascular resistance can be undesirable in some forms of dynamic ventricular outflow obstruction.

Therefore, PDE3 inhibitors require caution in conditions where stronger contraction may worsen an obstructive pressure gradient.

Sulfite Hypersensitivity – Modern Nuance

Some older inamrinone formulations contained sulfite preservatives.

The historical statement that asthma itself is an absolute contraindication is too broad.

Sulfite-sensitive individuals, particularly some patients with asthma, may be at greater risk of hypersensitivity reactions depending on the formulation.

Current product ingredients should be checked rather than assuming all PDE3 inhibitor preparations carry the same risk.

GI Decontamination

Modern milrinone and inamrinone toxicity is usually related to parenteral therapy, making gastrointestinal decontamination irrelevant in most cases.

For an unusual oral exposure:

• Do not induce vomiting.
• Routine gastric lavage is obsolete.

Activated charcoal might be considered only in selected recent clinically significant oral exposures when the airway is safe.

It should not delay cardiovascular stabilization.

No Specific Antidote

There is no specific reversal agent for inamrinone or milrinone toxicity.

Treatment consists of:

• Discontinuing exposure
• Hemodynamic support
• Correction of electrolytes
• Dysrhythmia treatment
• Management of complications

Extracorporeal Removal

Extracorporeal removal is not a routine antidotal strategy for PDE3 inhibitor toxicity.

In severe milrinone toxicity with renal dysfunction, management should involve toxicology, cardiology, and critical-care specialists because prolonged pharmacologic effects may occur.

Monitoring

Significant toxicity requires monitoring of:

• Blood pressure
• Heart rate
• ECG/rhythm
• Oxygenation
• Mental status
• Urine output
• Renal function
• Potassium
• Magnesium

Additional monitoring is guided by the clinical course.

Observation

The historical fixed 6-hour observation period should not be applied universally.

Duration depends on:

• Agent
• Route
• Magnitude of exposure
• Renal function
• Symptoms
• ECG findings
• Hemodynamic stability

Milrinone toxicity may be prolonged when renal clearance is impaired.

Admission

Monitored inpatient care is appropriate for:

• Persistent hypotension
• Significant dysrhythmia
• Evidence of poor organ perfusion
• Significant electrolyte abnormalities
• Renal dysfunction with suspected drug accumulation

Severe hemodynamic instability generally warrants intensive-care management.

Pregnancy

The historical FDA pregnancy letter category is obsolete.

Clinically significant toxicity during pregnancy should be treated according to maternal physiology.

Particularly important goals are maintaining:

• Maternal blood pressure
• Oxygenation
• Cardiac output
• Uteroplacental perfusion

Necessary treatment should not be withheld solely because of pregnancy.

Prognosis

Mild toxicity usually improves after:

• Drug discontinuation
• Clearance of the medication
• Correction of hemodynamic and electrolyte abnormalities

Prognosis becomes more serious when there is:

• Refractory shock
• Sustained ventricular dysrhythmia
• Severe underlying cardiac disease
• Renal failure causing prolonged milrinone exposure
• Multiorgan hypoperfusion

Important Modernization of the Older Source

• Amrinone is now generally called inamrinone.
• Inamrinone and milrinone are PDE3 inhibitors/inodilators.
• Milrinone has largely replaced inamrinone in contemporary practice.
• PDE3 inhibition → ↑ cAMP → increased cardiac contractility plus vascular relaxation.
• Acute toxicity is dominated by hypotension and dysrhythmias.
• Milrinone depends substantially on renal clearance; renal impairment can prolong toxicity.
• Inamrinone is more strongly associated with thrombocytopenia during prolonged exposure.
• Chronic oral PDE3 inhibitor therapy is not routine modern heart-failure treatment because long-term outcome data were unfavorable.
• Asthma alone is not a universal absolute contraindication; sulfite sensitivity depends partly on formulation.
• Routine Trendelenburg positioning is obsolete.
• Fluid resuscitation must be cautious in patients with heart failure.
• Persistent vasodilatory shock may require norepinephrine or another appropriately selected vasopressor.
• Atropine is relevant only when clinically important bradycardia is actually present.
• Routine gastric lavage is obsolete.
• There is no specific antidote.
• Observation should account for renal function and clinical trajectory rather than follow a fixed 6-hour rule.

Key Points

• Inamrinone/milrinone = PDE3 inhibitors.
• ↑ cAMP in myocardium → ↑ intracellular Ca²⁺ → positive inotropy.
• ↑ cAMP in vascular smooth muscle → vasodilation.
• Together these effects make them inodilators.
• Main acute toxicities: hypotension + dysrhythmias.
• Check and correct K⁺, Mg²⁺, and other relevant electrolyte abnormalities.
• Milrinone toxicity can be prolonged in renal impairment.
• Inamrinone can cause thrombocytopenia, especially with prolonged exposure.
• Stop an excessive infusion immediately and provide hemodynamic and rhythm support.
• No specific antidote exists.

237. Toxicology – Amrinone (Inamrinone) and Milrinone

Core Concept

Amrinone, now generally called inamrinone, and milrinone are phosphodiesterase-3 (PDE3) inhibitors with combined:

Positive inotropic effects – increase cardiac contractility   Vasodilator effects – decrease systemic and pulmonary vascular resistance

For this reason they are sometimes called inodilators.

Milrinone has largely replaced inamrinone in contemporary clinical practice because of more favorable pharmacologic and adverse-effect characteristics.

The major acute toxic effects are:

Excessive vasodilation → hypotension

and

Increased myocardial excitability → tachyarrhythmias/ventricular dysrhythmias

There is no specific antidote.

⸻

Modern Clinical Role

Milrinone may be used for short-term hemodynamic support in selected patients with:

Acute decompensated heart failure with low cardiac output   Severe ventricular dysfunction   Post-cardiac-surgery low-output states   Selected right ventricular failure   Selected pulmonary hypertension situations

Its use requires careful hemodynamic assessment because increased contractility may be offset by substantial vasodilation.

Inamrinone is now rarely used compared with milrinone.

⸻

PDE3 Physiology

Normally:

Adenylyl cyclase → cAMP

while:

PDE3 breaks down cAMP

PDE3 inhibition therefore increases intracellular cAMP.

⸻

Cardiac Mechanism

In cardiac myocytes:

PDE3 inhibition → ↑ cAMP → ↑ protein kinase A activity → ↑ intracellular Ca²⁺ availability → stronger contraction

The result is:

Increased myocardial contractility   Increased stroke volume   Increased cardiac output in appropriately selected patients

Unlike catecholamines, the drug does not require direct β-receptor stimulation to generate its primary inotropic effect.

⸻

Vascular Mechanism

In vascular smooth muscle, increased cAMP promotes relaxation.

Therefore:

PDE3 inhibition → vasodilation → ↓ systemic vascular resistance

It can also decrease pulmonary vascular resistance.

Thus the overall pharmacologic profile is:

↑ Contractility + ↓ afterload = inodilation

⸻

Why Hypotension Occurs

The same vasodilating action that may improve forward cardiac output can become excessive.

In toxicity:

Excessive vasodilation → ↓ SVR → hypotension → impaired organ perfusion

This is especially important in patients who already have:

Low blood pressure   Volume depletion   Severe heart failure   Other vasodilating medications

⸻

Toxic Dose

A reliable universal toxic threshold has not been established.

Most clinically important toxicity historically occurred through:

Therapeutic dosing errors   Excessive IV administration   Drug accumulation

Clinical severity is more useful than a reported amount.

⸻

Milrinone and Renal Function

Milrinone is substantially dependent on renal elimination.

Therefore:

Renal impairment → reduced clearance → prolonged exposure → greater risk of hypotension and dysrhythmias

Renal function is consequently an important consideration during both therapeutic use and suspected toxicity.

Dose accumulation may occur even without a single dramatic overdose.

⸻

Acute Cardiovascular Toxicity

The major findings are:

Hypotension   Tachycardia   Palpitations   Ventricular ectopy   Supraventricular dysrhythmias   Ventricular dysrhythmias

Severe hypotension can lead to:

Altered mental status   Myocardial ischemia   Acute kidney injury   Shock

⸻

Dysrhythmias

PDE3 inhibition can increase myocardial excitability.

Possible rhythm disturbances include:

Premature ventricular complexes   Atrial tachyarrhythmias   Ventricular tachycardia   Other ventricular dysrhythmias

Risk may be increased by:

Hypokalemia   Hypomagnesemia   Structural heart disease   Myocardial ischemia   Other proarrhythmic medications

⸻

Electrolytes

Electrolyte abnormalities can increase dysrhythmia risk.

Particular attention should be given to:

Potassium   Magnesium   Calcium

Hypokalemia may occur in patients receiving intensive heart-failure treatment, particularly when concurrent diuretics are being used.

⸻

Gastrointestinal Effects

Reported adverse effects include:

Nausea   Vomiting   Diarrhea   Abdominal discomfort

These are generally less important than cardiovascular toxicity during acute poisoning.

⸻

Thrombocytopenia

Inamrinone has historically been associated with thrombocytopenia, particularly during sustained therapy.

It is generally:

Dose/exposure related   Reversible after dose reduction or discontinuation

This adverse effect was one factor limiting long-term use.

Milrinone has a substantially lower tendency to produce this complication.

⸻

Hepatic Effects

Inamrinone has also been associated with:

Aminotransferase abnormalities   Rare clinically significant hepatotoxicity

This is more relevant to prolonged exposure than a brief acute overdose.

⸻

Why Chronic Oral PDE3 Therapy Fell Out of Favor

An important modern point is that chronic oral PDE3 inhibitor therapy for heart failure did not improve long-term survival and was associated with adverse outcomes.

Therefore, contemporary milrinone use is primarily short-term IV therapy in selected patients, rather than routine chronic oral heart-failure treatment.

⸻

Diagnosis

Diagnosis is based primarily on:

Medication history   Infusion history   Hemodynamic findings   ECG   Renal function   Electrolytes

There is no routinely useful serum inamrinone or milrinone concentration for emergency toxicologic decision-making.

⸻

Essential Assessment

In clinically important toxicity, evaluate:

Blood pressure   Heart rate   Mental status   Peripheral perfusion   ECG   Continuous cardiac rhythm

Laboratory evaluation may include:

Electrolytes   Potassium   Magnesium   Calcium   Creatinine   Glucose

Additional tests depend on severity.

⸻

Chronic-Therapy Evaluation

If adverse effects develop during prolonged inamrinone exposure, additional evaluation can include:

CBC with platelet count   Liver enzymes   Renal function   Electrolytes

For milrinone, renal function is especially important because impaired clearance can substantially prolong its effects.

⸻

Initial Management of IV Overdose

The first step in excessive IV administration is straightforward:

Stop the infusion.

Then assess:

Airway and breathing   Blood pressure and perfusion   Cardiac rhythm   Renal function   Electrolytes

Significant hypotension or dysrhythmia warrants monitored critical care.

⸻

Hypotension Management

Treatment depends on both volume status and cardiac function.

Appropriate isotonic crystalloid may be useful if the patient is volume depleted.

However, many patients receiving PDE3 inhibitors already have severe heart failure, so indiscriminate fluid loading may cause:

Pulmonary edema   Worsening congestion   Respiratory compromise

Fluid therapy should therefore be individualized.

⸻

Trendelenburg – Modern Correction

Routine Trendelenburg positioning is obsolete as treatment for hypotension.

It does not provide reliable sustained improvement in organ perfusion and may worsen respiratory mechanics in some patients.

⸻

Vasopressors

Persistent vasodilatory hypotension may require a vasopressor.

A vasoconstricting agent such as norepinephrine is commonly appropriate when significant vasodilatory shock persists.

Selection should account for:

Cardiac function   Rhythm   Degree of vasodilation   Perfusion   Other medications

⸻

Atropine

The historical source recommends atropine if hypotension is caused by bradycardia.

Atropine may be appropriate for clinically important symptomatic bradycardia, but bradycardia is not the characteristic toxicity of PDE3 inhibition.

Hypotension should not automatically be treated with atropine unless the heart-rate disturbance is actually contributing to poor perfusion.

⸻

Dysrhythmia Management

Management includes:

Stop the offending drug   Correct hypoxemia   Correct significant potassium abnormalities   Correct magnesium abnormalities   Treat acid–base disturbances   Evaluate myocardial ischemia   Follow contemporary resuscitation principles for unstable dysrhythmias

Electrical cardioversion/defibrillation is used when indicated by the rhythm and hemodynamic state.

⸻

Drug Interactions

Concomitant medications may amplify toxicity.

Examples include:

Other vasodilators → greater hypotension   Other positive inotropes → greater myocardial oxygen demand or arrhythmia risk   Diuretics → electrolyte depletion   Other proarrhythmic drugs → greater dysrhythmia risk

Medication compatibility is also important for IV therapy; drugs should not be mixed in the same line unless compatibility is established.

⸻

Outflow Obstruction

Increasing contractility while reducing vascular resistance can be undesirable in some forms of dynamic ventricular outflow obstruction.

Therefore, PDE3 inhibitors require caution in conditions where stronger contraction may worsen an obstructive pressure gradient.

⸻

Sulfite Hypersensitivity – Modern Nuance

Some older inamrinone formulations contained sulfite preservatives.

The historical statement that asthma itself is an absolute contraindication is too broad.

Sulfite-sensitive individuals, particularly some patients with asthma, may be at greater risk of hypersensitivity reactions depending on the formulation.

Current product ingredients should be checked rather than assuming all PDE3 inhibitor preparations carry the same risk.

⸻

GI Decontamination

Modern milrinone and inamrinone toxicity is usually related to parenteral therapy, making gastrointestinal decontamination irrelevant in most cases.

For an unusual oral exposure:

Do not induce vomiting.   Routine gastric lavage is obsolete.

Activated charcoal might be considered only in selected recent clinically significant oral exposures when the airway is safe.

It should not delay cardiovascular stabilization.

⸻

No Specific Antidote

There is no specific reversal agent for inamrinone or milrinone toxicity.

Treatment consists of:

Discontinuing exposure   Hemodynamic support   Correction of electrolytes   Dysrhythmia treatment   Management of complications

⸻

Extracorporeal Removal

Extracorporeal removal is not a routine antidotal strategy for PDE3 inhibitor toxicity.

In severe milrinone toxicity with renal dysfunction, management should involve toxicology, cardiology, and critical-care specialists because prolonged pharmacologic effects may occur.

⸻

Monitoring

Significant toxicity requires monitoring of:

Blood pressure   Heart rate   ECG/rhythm   Oxygenation   Mental status   Urine output   Renal function   Potassium   Magnesium

Additional monitoring is guided by the clinical course.

⸻

Observation

The historical fixed 6-hour observation period should not be applied universally.

Duration depends on:

Agent   Route   Magnitude of exposure   Renal function   Symptoms   ECG findings   Hemodynamic stability

Milrinone toxicity may be prolonged when renal clearance is impaired.

⸻

Admission

Monitored inpatient care is appropriate for:

Persistent hypotension   Significant dysrhythmia   Evidence of poor organ perfusion   Significant electrolyte abnormalities   Renal dysfunction with suspected drug accumulation

Severe hemodynamic instability generally warrants intensive-care management.

⸻

Pregnancy

The historical FDA pregnancy letter category is obsolete.

Clinically significant toxicity during pregnancy should be treated according to maternal physiology.

Particularly important goals are maintaining:

Maternal blood pressure   Oxygenation   Cardiac output   Uteroplacental perfusion

Necessary treatment should not be withheld solely because of pregnancy.

⸻

Prognosis

Mild toxicity usually improves after:

Drug discontinuation   Clearance of the medication   Correction of hemodynamic and electrolyte abnormalities

Prognosis becomes more serious when there is:

Refractory shock   Sustained ventricular dysrhythmia   Severe underlying cardiac disease   Renal failure causing prolonged milrinone exposure   Multiorgan hypoperfusion

⸻

Important Modernization of the Older Source

Amrinone is now generally called inamrinone.   Inamrinone and milrinone are PDE3 inhibitors/inodilators.   Milrinone has largely replaced inamrinone in contemporary practice.   PDE3 inhibition → ↑ cAMP → increased cardiac contractility plus vascular relaxation.   Acute toxicity is dominated by hypotension and dysrhythmias.   Milrinone depends substantially on renal clearance; renal impairment can prolong toxicity.   Inamrinone is more strongly associated with thrombocytopenia during prolonged exposure.   Chronic oral PDE3 inhibitor therapy is not routine modern heart-failure treatment because long-term outcome data were unfavorable.   Asthma alone is not a universal absolute contraindication; sulfite sensitivity depends partly on formulation.   Routine Trendelenburg positioning is obsolete.   Fluid resuscitation must be cautious in patients with heart failure.   Persistent vasodilatory shock may require norepinephrine or another appropriately selected vasopressor.   Atropine is relevant only when clinically important bradycardia is actually present.   Routine gastric lavage is obsolete.   There is no specific antidote.   Observation should account for renal function and clinical trajectory rather than follow a fixed 6-hour rule.

Key Points

Inamrinone/milrinone = PDE3 inhibitors.   ↑ cAMP in myocardium → ↑ intracellular Ca²⁺ → positive inotropy.   ↑ cAMP in vascular smooth muscle → vasodilation.   Together these effects make them inodilators.   Main acute toxicities: hypotension + dysrhythmias.   Check and correct K⁺, Mg²⁺, and other relevant electrolyte abnormalities.   Milrinone toxicity can be prolonged in renal impairment.   Inamrinone can cause thrombocytopenia, especially with prolonged exposure.   Stop an excessive infusion immediately and provide hemodynamic and rhythm support.   No specific antidote exists.

Toxicology – Amphetamines

Core Concept

Amphetamines are central nervous system stimulants and sympathomimetic drugs. They include prescription medications as well as illicitly manufactured stimulants.

Therapeutic amphetamine preparations are used mainly for:

• Attention-deficit/hyperactivity disorder (ADHD)
• Narcolepsy
• Selected other indications

The characteristic overdose syndrome is a sympathomimetic toxidrome:

Agitation + tachycardia + hypertension + mydriasis + diaphoresis + hyperthermia

Severe toxicity can progress to:

• Seizures
• Dangerous hyperthermia
• Rhabdomyolysis
• Dysrhythmias
• Myocardial ischemia
• Intracranial hemorrhage
• Shock
• Multiorgan failure

There is no specific antidote. Benzodiazepine-based sedation and aggressive supportive care are central to treatment.

Amphetamine-Type Stimulants

Clinically relevant agents include:

• Amphetamine
• Dextroamphetamine
• Mixed amphetamine salts
• Lisdexamfetamine
• Methamphetamine

Several drugs listed as “amphetamines” in older references are actually chemically or pharmacologically distinct stimulants or anorectic agents.

Many historical appetite suppressants listed in the source are also no longer commonly used because of safety concerns or regulatory changes.

Mechanism of Action

Amphetamines increase central and peripheral monoaminergic signaling.

Important mechanisms include:

• Increased presynaptic release of norepinephrine
• Increased release of dopamine
• Effects on serotonin at higher exposures or with particular agents
• Reversal/disruption of monoamine transport processes
• Intracellular effects involving vesicular monoamine storage

The older description of amphetamines as primarily direct α- and β-receptor agonists is incomplete.

Their major sympathomimetic effects arise predominantly from increased catecholamine availability.

Sympathomimetic Toxidrome

Typical findings include:

• Agitation
• Anxiety
• Restlessness
• Tachycardia
• Hypertension
• Mydriasis
• Diaphoresis
• Tremor
• Hyperreflexia
• Hyperthermia

Increasing toxicity can produce:

• Severe agitation
• Psychosis
• Seizures
• Cardiovascular complications
• Multiorgan injury

Amphetamine vs Antimuscarinic Toxicity

Both can produce:

• Agitation
• Tachycardia
• Mydriasis
• Hyperthermia

A useful distinction is:

Sympathomimetic → usually sweaty

Antimuscarinic → usually dry

Sympathomimetic patients often have marked diaphoresis and active bowel sounds, although no single physical finding is completely reliable.

Toxic Dose

There is no dependable universal toxic-dose threshold.

Severity varies with:

• Specific drug
• Formulation
• Route
• Patient size
• Individual sensitivity
• Chronic tolerance
• Coingestants
• Underlying cardiovascular disease

Therefore, management should be based on clinical toxicity rather than reported dose alone.

Tolerance in chronic users does not protect against catastrophic cardiovascular or hyperthermic complications.

Routes of Exposure

Amphetamine-type stimulants may be:

• Swallowed
• Insufflated
• Smoked
• Injected

The route influences:

• Speed of onset
• Peak concentration
• Duration
• Complication profile

Rapid-delivery routes can produce abrupt severe toxicity.

Neurologic Effects

Common manifestations include:

• Anxiety
• Agitation
• Tremor
• Headache
• Insomnia
• Hypervigilance
• Confusion

Severe toxicity can cause:

• Delirium
• Seizures
• Coma
• Intracranial hemorrhage
• Ischemic stroke

Psychiatric Effects

Amphetamine intoxication may produce:

• Paranoia
• Hallucinations
• Delusions
• Aggression
• Severe anxiety
• Stimulant-induced psychosis

Psychiatric symptoms may persist after peripheral sympathomimetic findings have improved.

Persistent psychosis requires reassessment for:

• Continued intoxication
• Sleep deprivation
• Coingestants
• Underlying psychiatric illness
• Other neurologic or metabolic disorders

Seizures

Seizures can result from intense CNS stimulation.

Complications include:

• Hypoxemia
• Lactic acidosis
• Hyperthermia
• Rhabdomyolysis
• Hyperkalemia
• Aspiration
• Acute kidney injury

Prompt control is essential.

Cardiovascular Effects

Common findings are:

• Sinus tachycardia
• Hypertension
• Palpitations

Severe toxicity may produce:

• Myocardial ischemia or infarction
• Coronary vasospasm
• Ventricular dysrhythmias
• Acute cardiomyopathy
• Acute heart failure
• Aortic dissection
• Shock

Young age does not exclude serious stimulant-associated cardiovascular disease.

Hypertension

Hypertension results from:

• Catecholamine excess
• Vasoconstriction
• Increased cardiac output
• Agitation

A major principle is:

Treat the hyperadrenergic state, not merely the blood-pressure number.

Sedation often improves both agitation and hypertension.

Severe Hypertensive Complications

Marked hypertension may contribute to:

• Intracranial hemorrhage
• Aortic dissection
• Myocardial ischemia
• Pulmonary edema
• Other end-organ injury

Persistent severe hypertension with acute organ injury requires titratable cardiovascular treatment in addition to sedation.

Hyperthermia

Severe hyperthermia is one of the most dangerous features of stimulant poisoning.

It can result from:

• Excessive motor activity
• Agitation
• Seizures
• Increased metabolic activity
• Catecholamine excess
• Impaired heat dissipation

Severe hyperthermia can rapidly produce:

• Rhabdomyolysis
• Hepatic injury
• Acute kidney injury
• Coagulopathy
• Cerebral injury
• Multiorgan failure

Hyperthermia Treatment

Management centers on:

• Rapid control of agitation
• External cooling
• Appropriate IV fluids
• Treatment of seizures
• Correction of physiologic abnormalities

Antipyretics such as acetaminophen do not correct stimulant hyperthermia because the problem is not an elevated hypothalamic fever set point.

Severe Agitation

Agitation itself can perpetuate:

Muscular activity → heat production → acidosis → rhabdomyolysis → worsening toxicity

Prompt sedation therefore has physiologic as well as behavioral importance.

Benzodiazepines

Benzodiazepines are generally first-line treatment for:

• Significant agitation
• Sympathomimetic excitation
• Seizures

They can also indirectly improve:

• Tachycardia
• Hypertension
• Hyperthermia caused by excessive muscular activity

Exact dosing should be titrated according to current emergency protocols and clinical response.

Refractory Agitation

Severe stimulant toxicity may require escalating sedation and intensive supportive management.

If dangerous agitation or hyperthermia cannot otherwise be controlled, advanced airway management and deep sedation may become necessary.

If neuromuscular paralysis is used:

Paralysis stops muscular activity but does not provide sedation or terminate cerebral seizure activity.

Adequate sedation and seizure treatment must continue.

Seizure Management

Benzodiazepines are first-line.

Refractory toxicologic seizures may require:

• Additional benzodiazepines
• Phenobarbital
• Appropriate anesthetic therapy for status epilepticus

Phenytoin – Modern Correction

The older recommendation to add phenytoin routinely is outdated.

Phenytoin is generally not preferred for toxin-induced seizures, because it does not effectively address many toxicologic seizure mechanisms.

Rhabdomyolysis

Rhabdomyolysis can result from:

• Hyperthermia
• Severe agitation
• Prolonged muscular activity
• Seizures
• Prolonged immobilization

Evaluate significant cases with:

• CK
• Potassium
• Creatinine
• Urinalysis
• Serial renal function

Treatment emphasizes appropriate fluid therapy and correction of electrolyte abnormalities.

Urinary Alkalinization

Routine urinary alkalinization is not recommended for stimulant-associated rhabdomyolysis.

It has not demonstrated clear benefit over appropriate supportive fluid management and can produce electrolyte and acid–base complications.

Renal Injury

Acute kidney injury may result from:

• Rhabdomyolysis
• Hyperthermia
• Hypotension
• Dehydration
• Severe systemic toxicity

Urine output and renal function should be monitored in severe poisoning.

Hepatic Injury

Severe hyperthermia and systemic toxicity can cause:

• Marked aminotransferase elevation
• Hepatic necrosis
• Acute liver failure

Liver injury is particularly concerning when accompanied by:

• Coagulopathy
• Hypoglycemia
• Lactic acidosis
• Encephalopathy

Coagulopathy

Extreme hyperthermia can trigger systemic coagulation abnormalities, including a DIC-like syndrome.

Monitor coagulation studies when severe hyperthermia or multiorgan injury develops.

Pulmonary Complications

Severe stimulant poisoning may cause:

• Aspiration
• Pulmonary edema
• Acute lung injury
• Respiratory failure

Respiratory compromise may also occur secondary to:

• Seizures
• CNS deterioration
• Severe cardiovascular toxicity

Acid–Base Disturbances

Lactic acidosis can result from:

• Severe agitation
• Seizures
• Hyperthermia
• Tissue hypoperfusion

Improvement often follows control of muscular activity, cooling, and restoration of perfusion.

Persistent severe acidosis should prompt investigation for shock, ongoing seizures, hyperthermia, or coingestants.

Electrolyte Abnormalities

Possible abnormalities include:

• Potassium disturbances
• Sodium disturbances
• Dehydration-related abnormalities

Electrolytes should be monitored closely in severe hyperthermia, seizures, or rhabdomyolysis.

Diagnosis

Amphetamine toxicity is primarily a clinical diagnosis.

Important information includes:

• Substance used
• Route
• Approximate timing
• Formulation
• Coingestants
• Prescription versus illicit source
• Duration of symptoms

Treatment should not wait for a urine drug screen when the clinical syndrome is convincing.

Urine Amphetamine Screening

Immunoassay drug screens have important limitations.

Possible problems include:

• False-positive results
• False-negative results
• Cross-reactivity with medications
• Inability to establish degree of intoxication
• Inability to prove that detected drug caused the current syndrome

A positive urine result indicates exposure within the detection window, not necessarily current clinical toxicity.

Confirmatory mass-spectrometric testing may be used when definitive identification matters.

Laboratory Evaluation

Minor uncomplicated intoxication may require limited testing.

Significant toxicity may warrant:

• Electrolytes
• Bicarbonate
• Creatinine
• Glucose
• CK
• Liver tests
• Blood gas and/or lactate
• Coagulation studies in severe hyperthermia
• Urinalysis

Intentional overdose may also require evaluation for important occult coingestants.

ECG and Cardiac Evaluation

Obtain an ECG when clinically significant toxicity is present.

Continuous monitoring is appropriate for:

• Severe tachycardia
• Chest pain
• Significant hypertension
• Dysrhythmia
• Hyperthermia
• Severe intoxication

Chest pain or ischemic findings should prompt appropriate evaluation for acute coronary injury.

Neurologic Imaging

Head CT is not required simply because a patient used amphetamines.

It becomes important when there is:

• Severe or unusual headache
• Focal neurologic deficit
• Persistent altered consciousness
• Suspected intracranial hemorrhage
• Trauma
• Seizure with concerning features

Lumbar puncture is likewise based on the differential diagnosis rather than routinely performed for stimulant intoxication.

Initial Management

Priorities are:

Airway/breathing → control agitation/seizures → measure core temperature → assess circulation → rapidly cool severe hyperthermia → identify end-organ injury

Benzodiazepine-based sedation is a central early intervention.

Hypertension Management

Many patients improve substantially after:

• Sedation
• Reduced stimulation
• Control of hyperthermia

Persistent severe hypertension with end-organ injury may require a short-acting titratable antihypertensive/vasodilator chosen according to the clinical problem.

The historical reliance on nitroprusside as the default drug is no longer necessary because several titratable agents are available.

β-Blockers – Important Nuance

Older teaching warned against every β-blocker in stimulant toxicity because of theoretical “unopposed α stimulation.”

Modern evidence is more nuanced and does not support treating all β-blockers as universally contraindicated.

However, in acute sympathomimetic poisoning:

• Sedation remains foundational.
• Drug selection should match the cardiovascular complication.
• Pure β-blockade is generally not the first reflexive treatment for an undifferentiated hyperadrenergic patient.

Management of myocardial ischemia, dysrhythmia, or severe hypertension should follow current toxicology/cardiology guidance.

Hypotension

Hypotension in severe poisoning may indicate:

• Volume depletion
• Hyperthermic collapse
• Cardiomyopathy
• Dysrhythmia
• Acidosis
• Multiorgan failure
• Coingestion

Treatment depends on the cause.

Appropriate crystalloid may be given when volume depletion is present, while persistent shock may require vasopressors and assessment of cardiac function.

Routine Trendelenburg positioning is obsolete.

GI Decontamination

Do not induce vomiting.

The historical routine use of gastric lavage is also obsolete.

A single dose of activated charcoal may occasionally be considered after a substantial recent oral ingestion if:

• Presentation is early
• The airway is safe
• The expected benefit outweighs aspiration risk

It should never delay treatment of agitation, seizures, hyperthermia, or cardiovascular instability.

Drug Packets

Suspected internal concealment of stimulant packets is a separate clinical problem.

Distinguish:

• Body packers – planned ingestion of multiple well-wrapped packets
• Body stuffers – hurried concealment of fewer, less securely wrapped packets

Packet rupture can cause abrupt life-threatening sympathomimetic poisoning.

Asymptomatic intact body packers may be candidates for monitored whole-bowel irrigation according to specialist protocols.

Packet rupture or severe toxicity may require urgent surgical and critical-care management.

Imaging for Drug Packets

The historical recommendation for routine abdominal radiographs is incomplete.

CT is generally more sensitive than plain abdominal radiography for detecting body-packing packets.

A negative plain film does not reliably exclude concealed packets.

No Specific Antidote

There is no direct antidote for amphetamine poisoning.

Treatment is based on:

• Sedation
• Cooling
• Seizure control
• Cardiovascular support
• Management of rhabdomyolysis
• Treatment of organ complications

Observation

The historical universal 4–6-hour observation rule is too rigid.

Duration depends on:

• Immediate-release versus extended-release formulation
• Specific drug
• Route
• Amount
• Clinical symptoms
• Coingestants
• Persistent psychiatric symptoms
• Vital signs
• Evidence of end-organ injury

Long-acting or modified-release products may produce prolonged toxicity.

Admission

Hospital admission is appropriate for clinically significant:

• Persistent agitation
• Recurrent seizures
• Hyperthermia
• Persistent severe tachycardia or hypertension
• Dysrhythmia
• Chest pain or ischemia
• Rhabdomyolysis
• Acute kidney injury
• Hepatic injury
• Coagulopathy
• Altered mental status

Severe hyperthermia or multiorgan toxicity generally warrants intensive care.

Chronic Stimulant Use

Long-term or repeated use can be associated with:

• Weight loss
• Sleep deprivation
• Psychiatric symptoms
• Cardiomyopathy
• Hypertension
• Vascular complications
• Dental and nutritional problems depending on circumstances
• Substance-use disorder

Injection additionally creates risks unrelated to the stimulant molecule itself, including:

• Endocarditis
• Abscess
• Blood-borne infections
• Sepsis

Stimulant Withdrawal

After prolonged heavy use, abrupt cessation can produce:

• Fatigue
• Hypersomnia
• Depressed mood
• Increased appetite
• Psychomotor slowing or agitation
• Craving

Severe depression and suicidality require direct assessment.

Withdrawal is generally not characterized by the autonomic instability seen with alcohol or sedative-hypnotic withdrawal.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Amphetamine exposure during pregnancy should be assessed according to:

• Therapeutic versus nonmedical exposure
• Dose and frequency
• Maternal cardiovascular effects
• Nutrition
• Other substances
• Obstetric status

Severe maternal hyperthermia, hypertension, hypoxemia, or seizures require prompt treatment because maternal instability threatens fetal perfusion and oxygenation.

Safeguarding

Rigid age-based assumptions about neglect, abuse, or intentional poisoning are outdated.

Pediatric exposure should instead be evaluated according to:

• Developmental ability
• Accessibility
• Exposure circumstances
• Consistency of the history
• Recurrent unexplained exposures
• Overall safeguarding concerns

Important Modernization of the Older Source

• Amphetamines primarily increase catecholamine and dopamine signaling rather than simply acting as direct α/β agonists.
• The classic presentation is a sympathomimetic toxidrome.
• Severe hyperthermia is a medical emergency and can rapidly cause rhabdomyolysis, liver failure, coagulopathy, AKI, and brain injury.
• Benzodiazepines are foundational treatment for agitation and seizures.
• Antipyretics do not treat stimulant-induced hyperthermia.
• Phenytoin is generally not preferred for toxicologic seizures.
• Paralysis does not treat cerebral seizure activity and must never substitute for sedation.
• Hypertension often improves after adequate sedation.
• Modern evidence does not support an absolute blanket prohibition on every β-blocker in all stimulant-associated cardiovascular presentations.
• Trendelenburg positioning and routine dopamine-first shock treatment are outdated.
• Routine urinary alkalinization is not recommended for rhabdomyolysis.
• Urine amphetamine screens can be misleading and do not measure severity.
• Routine gastric lavage is obsolete.
• Activated charcoal has only a selective role after recent oral exposure with a safe airway.
• CT is generally more sensitive than plain radiography for body-packet detection.
• There is no specific antidote.
• Observation should be formulation- and symptom-based rather than a universal 4–6-hour rule.

Key Points

• Amphetamines → catecholamine excess → sympathomimetic toxidrome.
• Think agitation + tachycardia + hypertension + mydriasis + diaphoresis + hyperthermia.
• Benzodiazepines are first-line for significant agitation and seizures.
• Severe hyperthermia requires rapid sedation and active cooling.
• Major complications include seizures, stroke, myocardial ischemia, dysrhythmias, rhabdomyolysis, AKI, hepatic injury, and coagulopathy.
• Urine drug screens confirm neither current intoxication nor severity.
• Treat hypertension initially by controlling the hyperadrenergic state; persistent end-organ-threatening hypertension may require titratable cardiovascular therapy.
• Do not induce vomiting or routinely perform gastric lavage.
• No specific antidote exists.

Toxicology – Ammonia

Core Concept

Ammonia (NH₃) is a highly water-soluble, alkaline irritant gas with a strong pungent odor.

Important forms include:

• Anhydrous ammonia – concentrated gas or pressurized/liquefied ammonia used industrially
• Aqueous ammonia – ammonia dissolved in water
• Dilute household cleaning products
• More concentrated industrial/commercial solutions

The major toxic effect is direct chemical injury at the site of contact, especially involving:

• Eyes
• Upper airway
• Lungs
• Skin
• Gastrointestinal tract

There is no specific antidote.

Common Sources and Uses

Ammonia is used in:

• Fertilizer production
• Refrigeration systems
• Chemical manufacturing
• Plastics and synthetic fibers
• Pharmaceutical and dye production
• Industrial cleaning
• Household cleaning products

Severe exposures are particularly associated with:

• Industrial spills
• Refrigeration accidents
• Agricultural exposure
• Pressurized anhydrous ammonia
• Concentrated cleaning solutions

Routes of Exposure

Toxicity can occur through:

• Inhalation
• Ocular exposure
• Dermal contact
• Ingestion

Severity depends strongly on:

• Concentration
• Duration
• Route
• Amount
• Enclosed-space exposure
• Delay before decontamination

Mechanism of Injury

Ammonia is extremely soluble in water.

On contact with moist tissues, ammonia produces an alkaline environment traditionally represented as:

NH₃ + H₂O ⇌ NH₄⁺ + OH⁻

The resulting hydroxide-rich environment causes direct chemical injury.

Alkaline injury can produce:

• Protein disruption
• Cell membrane damage
• Inflammation
• Tissue penetration
• Liquefactive-type necrosis in substantial exposures

Why the Eyes and Airways Are Vulnerable

The:

• Tear film
• Nasal mucosa
• Oropharynx
• Respiratory epithelium

contain abundant water.

Ammonia therefore dissolves rapidly at these surfaces, explaining its intense immediate irritant effect.

Anhydrous Ammonia

Anhydrous ammonia is particularly hazardous because it may be stored under pressure as a liquefied gas.

Release can cause:

• Very high local vapor concentrations
• Severe inhalational injury
• Chemical burns
• Eye injury

Contact with liquefied ammonia can also produce cold-related tissue injury from rapid evaporation in addition to chemical injury.

Inhalational Toxicity

Because ammonia is highly water soluble, much of the initial injury occurs in the upper respiratory tract.

Symptoms may include:

• Burning of the nose and throat
• Cough
• Hoarseness
• Chest discomfort
• Dyspnea
• Wheezing
• Tachypnea

More severe exposure can produce:

• Laryngeal edema
• Laryngospasm
• Stridor
• Bronchospasm
• Chemical pneumonitis
• Acute lung injury
• Noncardiogenic pulmonary edema
• Respiratory failure

Airway Injury

Upper-airway injury is one of the most important immediate threats.

Warning findings include:

• Stridor
• Progressive hoarseness
• Drooling
• Dysphagia
• Respiratory distress
• Oropharyngeal burns
• Increasing work of breathing
• Altered mental status

Airway edema can progress after exposure.

Therefore:

A threatened airway should be secured before edema makes airway management substantially more difficult.

Pulmonary Injury

Lower-airway injury may produce:

• Cough
• Wheezing
• Bronchospasm
• Crackles
• Hypoxemia
• Chemical pneumonitis
• Acute lung injury

Pulmonary edema may evolve after a substantial exposure.

An initially reassuring examination or chest radiograph does not completely exclude evolving lung injury.

Reactive Airways Dysfunction

After significant irritant exposure, some patients can develop persistent airway hyperreactivity, sometimes described as reactive airways dysfunction syndrome (RADS).

Persistent symptoms may include:

• Cough
• Wheezing
• Chest tightness
• Exercise intolerance

Significant exposures may therefore require pulmonary follow-up.

Eye Exposure

Ammonia can rapidly cause severe ocular injury.

Possible manifestations include:

• Burning pain
• Lacrimation
• Conjunctival injection
• Blepharospasm
• Corneal epithelial injury
• Corneal burns
• Visual impairment

High-concentration exposure can threaten vision.

Immediate Ocular Management

The priority is:

Immediate copious irrigation

Do not delay irrigation to:

• Identify the exact concentration
• Measure ocular pH
• Perform a detailed examination

After initial irrigation, ocular pH can help determine whether additional irrigation is required.

Persistent:

• Pain
• Photophobia
• Visual disturbance
• Corneal abnormalities

requires urgent ophthalmic evaluation.

Skin Exposure

Dermal exposure may produce:

• Pain
• Erythema
• Irritant dermatitis
• Blistering
• Chemical burns
• Deeper tissue injury after concentrated exposure

Liquefied anhydrous ammonia may additionally cause cold injury.

Dermal Decontamination

Management begins with:

• Removal from the contaminated environment
• Removal of contaminated clothing
• Copious irrigation
• Standard assessment of resulting chemical/cold burns

Significant burns should be managed according to burn-care principles.

Ingestion

Aqueous ammonia ingestion primarily produces corrosive gastrointestinal injury.

Possible symptoms include:

• Oral pain
• Drooling
• Dysphagia
• Odynophagia
• Vomiting
• Chest pain
• Abdominal pain

Severe exposure can injure:

• Oropharynx
• Esophagus
• Stomach

Absence of Oral Burns Does Not Exclude Deeper Injury

A normal-looking mouth does not reliably exclude esophageal or gastric injury after a significant caustic ingestion.

Assessment should therefore consider:

• Product concentration
• Amount
• Intent
• Drooling
• Dysphagia/odynophagia
• Chest or abdominal pain
• Vomiting
• Respiratory findings

GI Complications

Severe corrosive injury may result in:

• Ulceration
• Necrosis
• Perforation
• Mediastinitis or peritonitis
• Later esophageal stricture formation

Long-term swallowing problems may therefore develop after significant injury.

Do Not Induce Vomiting

Vomiting should never be intentionally induced after ammonia ingestion.

Re-exposure of the upper GI tract can worsen injury and increase aspiration risk.

Ipecac has no role.

Do Not Neutralize

Do not attempt to neutralize ammonia with an acid.

Chemical neutralization can:

• Generate heat
• Produce additional tissue damage
• Delay appropriate care

The same general principle applies to caustic ingestions:

Do not attempt home chemical neutralization.

Routine Gastric Lavage Is Contraindicated

Gastric lavage is generally inappropriate after caustic ammonia ingestion because it can:

• Re-expose injured tissue
• Increase perforation risk
• Cause aspiration
• Produce additional mechanical trauma

Activated Charcoal

Activated charcoal is generally not useful for ammonia ingestion.

It does not meaningfully prevent the immediate local corrosive injury and may interfere with subsequent endoscopic evaluation.

Oral Dilution – Modern Perspective

Older references sometimes recommended routine administration of water or milk after caustic ingestion.

Modern management does not rely on routine forced dilution.

Do not give large volumes because this may:

• Trigger vomiting
• Increase gastric distension
• Increase aspiration risk

Immediate advice after ingestion should follow current poison-center or caustic-ingestion guidance.

Ammonia + Bleach

Mixing ammonia-containing cleaners with hypochlorite bleach can generate chloramine gases and related respiratory irritants.

This can cause:

• Eye and throat irritation
• Cough
• Chest tightness
• Bronchospasm
• Dyspnea
• Chemical pneumonitis in substantial exposure

The resulting illness should be managed as an irritant gas inhalation, rather than assuming exposure to ammonia alone.

Reactive Airway Disease

Patients with:

• Asthma
• Other reactive airway disease

may experience more pronounced bronchospasm after ammonia or chloramine exposure.

Diagnosis

Diagnosis is usually based on:

• Exposure history
• Product concentration
• Route
• Duration
• Respiratory examination
• Ocular/skin findings
• GI symptoms after ingestion

There is no clinically useful routine serum “ammonia level” for diagnosing inhalational or caustic ammonia exposure.

A plasma ammonia measurement used in hepatic encephalopathy evaluates an entirely different clinical problem.

Laboratory Evaluation

Minor asymptomatic exposure may require no laboratory testing.

For significant inhalational injury, testing may include:

• Pulse oximetry
• Blood gas when respiratory compromise is present
• Electrolytes and other general tests when clinically indicated

Severe caustic ingestion may require additional laboratory evaluation based on the extent of systemic illness.

Chest Imaging

Chest radiography is appropriate when there are significant respiratory symptoms or suspected pulmonary injury.

Possible findings include:

• Infiltrates
• Pulmonary edema
• Other evidence of acute lung injury

However:

A normal early chest radiograph does not exclude evolving inhalational injury.

Bronchoscopy

Bronchoscopy is not automatically required after every ammonia exposure.

It may be considered after substantial inhalation when clinicians need to evaluate significant airway injury.

Airway stabilization always takes priority over diagnostic bronchoscopy.

Endoscopy After Ingestion

Upper GI endoscopy may be appropriate after clinically significant caustic ingestion, particularly when there are concerning symptoms or a substantial concentrated exposure.

It can help assess:

• Esophageal injury
• Gastric injury
• Severity and prognosis

Timing and need should follow contemporary caustic-ingestion protocols and specialist assessment rather than an automatic rule that every exposure undergo endoscopy.

Initial Management – Inhalation

Priorities are:

• Remove from exposure
• Protect rescuers from contamination
• Assess airway immediately
• Provide oxygen when indicated
• Treat bronchospasm
• Monitor for progressive airway or pulmonary injury

Severe exposure warrants early involvement of airway/critical-care specialists.

Oxygen

Supplemental oxygen is appropriate for:

• Hypoxemia
• Respiratory distress
• Significant inhalational injury

The historical routine recommendation for 100% oxygen after every ammonia exposure is unnecessary in a patient with trivial exposure and normal respiratory status.

Bronchospasm

Clinically significant wheezing or airflow obstruction can be treated with an inhaled β₂-agonist bronchodilator.

Patients with severe bronchospasm require close respiratory monitoring.

Corticosteroids

Routine corticosteroids have not been proven to prevent ammonia-induced pulmonary injury.

They should not automatically be administered after every inhalation.

They may be used when another established indication exists, such as a clinically important asthma exacerbation.

Antibiotics

Prophylactic antibiotics are not routinely indicated for uncomplicated chemical pneumonitis.

They are reserved for suspected or demonstrated infection or another specific indication.

Severe Lung Injury

Progressive respiratory failure is treated with standard supportive respiratory care.

This may include:

• Supplemental oxygen
• Appropriate noninvasive support in selected patients
• Endotracheal intubation when necessary
• Lung-protective mechanical ventilation for severe acute lung injury

There is no ammonia-specific antidotal therapy.

No Specific Antidote

There is no antidote for ammonia poisoning.

Treatment consists of:

Exposure termination + immediate decontamination + airway management + supportive respiratory/GI/burn care

Monitoring

Symptomatic patients may require monitoring of:

• Respiratory rate and effort
• Oxygen saturation
• Airway findings
• Heart rate and blood pressure
• Lung examination
• Mental status

After significant ingestion, monitor for:

• Dysphagia
• Chest/abdominal pain
• GI bleeding
• Perforation
• Subsequent stricture formation

Observation and Disposition

A fixed historical 6-hour rule should not be applied to every exposure.

Observation depends on:

• Concentration
• Route
• Duration
• Symptoms
• Respiratory findings
• Ocular/dermal injury
• Evidence of caustic GI injury
• Clinical trajectory

Patients with significant airway injury, hypoxemia, bronchospasm, pulmonary injury, or substantial caustic ingestion generally require continued hospital management.

Long-Term Complications

After inhalation

Possible persistent complications include:

• Airway hyperreactivity
• Chronic cough
• Obstructive abnormalities
• Other residual pulmonary dysfunction after severe injury

After ingestion

Severe esophageal injury may heal with:

• Fibrosis
• Stricture formation
• Chronic dysphagia

Follow-up is therefore important after substantial caustic injury.

Safeguarding

The older source uses rigid age thresholds for suspected neglect or intentional poisoning.

Modern assessment instead considers:

• Developmental ability
• Accessibility of the chemical
• Circumstances of exposure
• Consistency of the history
• Previous unexplained injuries or poisonings

Age alone does not establish abuse or neglect.

Occupational Exposure

Anhydrous ammonia is an important occupational hazard.

Prevention depends on:

• Engineering controls
• Appropriate respiratory/eye/skin protection
• Safe handling of pressurized systems
• Emergency decontamination capability

Historical numerical exposure limits should be verified against current occupational standards for the relevant jurisdiction.

Important Modernization of the Older Source

• Ammonia is a highly water-soluble alkaline irritant producing direct chemical injury.
• High-concentration inhalation can cause upper-airway edema, bronchospasm, chemical pneumonitis, acute lung injury, and respiratory failure.
• Liquefied anhydrous ammonia can cause both chemical and cold-related tissue injury.
• A normal early chest X-ray does not exclude evolving lung injury.
• Airway edema can progress; a threatened airway should be managed early.
• Immediate copious irrigation is the priority for ocular and dermal exposure.
• Do not delay eye irrigation to measure pH first.
• Significant ingestion is managed according to caustic-ingestion principles.
• Absence of visible oral burns does not exclude deeper esophageal injury.
• Do not induce vomiting.
• Do not attempt acid–base neutralization.
• Routine gastric lavage and activated charcoal are inappropriate.
• Routine forced dilution with large volumes of water or milk is no longer a standard strategy.
• Bronchoscopy and GI endoscopy are used selectively according to severity and specialist assessment.
• Bronchodilators are appropriate for bronchospasm.
• Routine corticosteroids have not been proven to prevent ammonia lung injury.
• There is no specific antidote.
• Mixing ammonia with hypochlorite bleach can generate chloramine-type irritant gases.
• Fixed historical observation periods should be replaced by exposure- and symptom-based assessment.

Key Points

• NH₃ + moist tissue → alkaline environment → direct chemical injury.
• Major targets are the eyes, upper airway, lungs, skin, esophagus, and stomach.
• Concentrated/anhydrous ammonia can rapidly cause airway edema and severe respiratory injury.
• Watch for stridor, hoarseness, drooling, wheezing, hypoxemia, and increasing respiratory distress.
• An initially normal chest radiograph does not rule out evolving lung injury.
• Eye or skin exposure requires immediate copious irrigation.
• Significant ingestion is treated as a caustic alkali exposure.
• Never induce vomiting or attempt chemical neutralization.
• Activated charcoal has no routine role.
• Treat bronchospasm supportively and secure a threatened airway early.
• No specific antidote exists.

Common Sources and Uses Ammonia is used in:  Fertilizer production Refrigeration systems Chemical manufacturing Plastics and synthetic fibers Pharmaceutical and dye production Industrial cleaning Household cleaning products  Severe exposures are particularly associated with:  Industrial spills Refrigeration accidents Agricultural exposure Pressurized anhydrous ammonia Concentrated cleaning solutions

Routes of Exposure Toxicity can occur through:  Inhalation Ocular exposure Dermal contact Ingestion  Severity depends strongly on:  Concentration Duration Route Amount Enclosed-space exposure Delay before decontamination

Mechanism of Injury Ammonia is extremely soluble in water. On contact with moist tissues, ammonia produces an alkaline environment traditionally represented as: NH₃ + H₂O ⇌ NH₄⁺ + OH⁻ The resulting hydroxide-rich environment causes direct chemical injury. Alkaline injury can produce:  Protein disruption Cell membrane damage Inflammation Tissue penetration Liquefactive-type necrosis in substantial exposures

Why the Eyes and Airways Are Vulnerable The:  Tear film Nasal mucosa Oropharynx Respiratory epithelium  contain abundant water. Ammonia therefore dissolves rapidly at these surfaces, explaining its intense immediate irritant effect.

Anhydrous Ammonia Anhydrous ammonia is particularly hazardous because it may be stored under pressure as a liquefied gas. Release can cause:  Very high local vapor concentrations Severe inhalational injury Chemical burns Eye injury  Contact with liquefied ammonia can also produce cold-related tissue injury from rapid evaporation in addition to chemical injury.

Inhalational Toxicity Because ammonia is highly water soluble, much of the initial injury occurs in the upper respiratory tract. Symptoms may include:  Burning of the nose and throat Cough Hoarseness Chest discomfort Dyspnea Wheezing Tachypnea  More severe exposure can produce:  Laryngeal edema Laryngospasm Stridor Bronchospasm Chemical pneumonitis Acute lung injury Noncardiogenic pulmonary edema Respiratory failure

Airway Injury Upper-airway injury is one of the most important immediate threats. Warning findings include:  Stridor Progressive hoarseness Drooling Dysphagia Respiratory distress Oropharyngeal burns Increasing work of breathing Altered mental status  Airway edema can progress after exposure. Therefore: A threatened airway should be secured before edema makes airway management substantially more difficult.

Pulmonary Injury Lower-airway injury may produce:  Cough Wheezing Bronchospasm Crackles Hypoxemia Chemical pneumonitis Acute lung injury  Pulmonary edema may evolve after a substantial exposure. An initially reassuring examination or chest radiograph does not completely exclude evolving lung injury.

Reactive Airways Dysfunction After significant irritant exposure, some patients can develop persistent airway hyperreactivity, sometimes described as reactive airways dysfunction syndrome (RADS). Persistent symptoms may include:  Cough Wheezing Chest tightness Exercise intolerance  Significant exposures may therefore require pulmonary follow-up.

Eye Exposure Ammonia can rapidly cause severe ocular injury. Possible manifestations include:  Burning pain Lacrimation Conjunctival injection Blepharospasm Corneal epithelial injury Corneal burns Visual impairment  High-concentration exposure can threaten vision.

Immediate Ocular Management The priority is: Immediate copious irrigation Do not delay irrigation to:  Identify the exact concentration Measure ocular pH Perform a detailed examination  After initial irrigation, ocular pH can help determine whether additional irrigation is required. Persistent:  Pain Photophobia Visual disturbance Corneal abnormalities  requires urgent ophthalmic evaluation.

Skin Exposure Dermal exposure may produce:  Pain Erythema Irritant dermatitis Blistering Chemical burns Deeper tissue injury after concentrated exposure  Liquefied anhydrous ammonia may additionally cause cold injury.

Dermal Decontamination Management begins with:  Removal from the contaminated environment Removal of contaminated clothing Copious irrigation Standard assessment of resulting chemical/cold burns  Significant burns should be managed according to burn-care principles.

Ingestion Aqueous ammonia ingestion primarily produces corrosive gastrointestinal injury. Possible symptoms include:  Oral pain Drooling Dysphagia Odynophagia Vomiting Chest pain Abdominal pain  Severe exposure can injure:  Oropharynx Esophagus Stomach

Absence of Oral Burns Does Not Exclude Deeper Injury A normal-looking mouth does not reliably exclude esophageal or gastric injury after a significant caustic ingestion. Assessment should therefore consider:  Product concentration Amount Intent Drooling Dysphagia/odynophagia Chest or abdominal pain Vomiting Respiratory findings

GI Complications Severe corrosive injury may result in:  Ulceration Necrosis Perforation Mediastinitis or peritonitis Later esophageal stricture formation  Long-term swallowing problems may therefore develop after significant injury.

Do Not Induce Vomiting Vomiting should never be intentionally induced after ammonia ingestion. Re-exposure of the upper GI tract can worsen injury and increase aspiration risk. Ipecac has no role.

Do Not Neutralize Do not attempt to neutralize ammonia with an acid. Chemical neutralization can:  Generate heat Produce additional tissue damage Delay appropriate care  The same general principle applies to caustic ingestions: Do not attempt home chemical neutralization.

Routine Gastric Lavage Is Contraindicated Gastric lavage is generally inappropriate after caustic ammonia ingestion because it can:  Re-expose injured tissue Increase perforation risk Cause aspiration Produce additional mechanical trauma

Activated Charcoal Activated charcoal is generally not useful for ammonia ingestion. It does not meaningfully prevent the immediate local corrosive injury and may interfere with subsequent endoscopic evaluation.

Oral Dilution – Modern Perspective Older references sometimes recommended routine administration of water or milk after caustic ingestion. Modern management does not rely on routine forced dilution. Do not give large volumes because this may:  Trigger vomiting Increase gastric distension Increase aspiration risk  Immediate advice after ingestion should follow current poison-center or caustic-ingestion guidance.

Ammonia + Bleach Mixing ammonia-containing cleaners with hypochlorite bleach can generate chloramine gases and related respiratory irritants. This can cause:  Eye and throat irritation Cough Chest tightness Bronchospasm Dyspnea Chemical pneumonitis in substantial exposure  The resulting illness should be managed as an irritant gas inhalation, rather than assuming exposure to ammonia alone.

Reactive Airway Disease Patients with:  Asthma Other reactive airway disease  may experience more pronounced bronchospasm after ammonia or chloramine exposure.

Diagnosis Diagnosis is usually based on:  Exposure history Product concentration Route Duration Respiratory examination Ocular/skin findings GI symptoms after ingestion  There is no clinically useful routine serum “ammonia level” for diagnosing inhalational or caustic ammonia exposure. A plasma ammonia measurement used in hepatic encephalopathy evaluates an entirely different clinical problem.

Laboratory Evaluation Minor asymptomatic exposure may require no laboratory testing. For significant inhalational injury, testing may include:  Pulse oximetry Blood gas when respiratory compromise is present Electrolytes and other general tests when clinically indicated  Severe caustic ingestion may require additional laboratory evaluation based on the extent of systemic illness.

Chest Imaging Chest radiography is appropriate when there are significant respiratory symptoms or suspected pulmonary injury. Possible findings include:  Infiltrates Pulmonary edema Other evidence of acute lung injury  However: A normal early chest radiograph does not exclude evolving inhalational injury.

Bronchoscopy Bronchoscopy is not automatically required after every ammonia exposure. It may be considered after substantial inhalation when clinicians need to evaluate significant airway injury. Airway stabilization always takes priority over diagnostic bronchoscopy.

Endoscopy After Ingestion Upper GI endoscopy may be appropriate after clinically significant caustic ingestion, particularly when there are concerning symptoms or a substantial concentrated exposure. It can help assess:  Esophageal injury Gastric injury Severity and prognosis  Timing and need should follow contemporary caustic-ingestion protocols and specialist assessment rather than an automatic rule that every exposure undergo endoscopy.

Initial Management – Inhalation Priorities are:  Remove from exposure Protect rescuers from contamination Assess airway immediately Provide oxygen when indicated Treat bronchospasm Monitor for progressive airway or pulmonary injury  Severe exposure warrants early involvement of airway/critical-care specialists.

Oxygen Supplemental oxygen is appropriate for:  Hypoxemia Respiratory distress Significant inhalational injury  The historical routine recommendation for 100% oxygen after every ammonia exposure is unnecessary in a patient with trivial exposure and normal respiratory status.

Bronchospasm Clinically significant wheezing or airflow obstruction can be treated with an inhaled β₂-agonist bronchodilator. Patients with severe bronchospasm require close respiratory monitoring.

Corticosteroids Routine corticosteroids have not been proven to prevent ammonia-induced pulmonary injury. They should not automatically be administered after every inhalation. They may be used when another established indication exists, such as a clinically important asthma exacerbation.

Antibiotics Prophylactic antibiotics are not routinely indicated for uncomplicated chemical pneumonitis. They are reserved for suspected or demonstrated infection or another specific indication.

Severe Lung Injury Progressive respiratory failure is treated with standard supportive respiratory care. This may include:  Supplemental oxygen Appropriate noninvasive support in selected patients Endotracheal intubation when necessary Lung-protective mechanical ventilation for severe acute lung injury  There is no ammonia-specific antidotal therapy.

No Specific Antidote There is no antidote for ammonia poisoning. Treatment consists of: Exposure termination + immediate decontamination + airway management + supportive respiratory/GI/burn care

Monitoring Symptomatic patients may require monitoring of:  Respiratory rate and effort Oxygen saturation Airway findings Heart rate and blood pressure Lung examination Mental status  After significant ingestion, monitor for:  Dysphagia Chest/abdominal pain GI bleeding Perforation Subsequent stricture formation

Observation and Disposition A fixed historical 6-hour rule should not be applied to every exposure. Observation depends on:  Concentration Route Duration Symptoms Respiratory findings Ocular/dermal injury Evidence of caustic GI injury Clinical trajectory  Patients with significant airway injury, hypoxemia, bronchospasm, pulmonary injury, or substantial caustic ingestion generally require continued hospital management.

Long-Term Complications After inhalation Possible persistent complications include:  Airway hyperreactivity Chronic cough Obstructive abnormalities Other residual pulmonary dysfunction after severe injury  After ingestion Severe esophageal injury may heal with:  Fibrosis Stricture formation Chronic dysphagia  Follow-up is therefore important after substantial caustic injury.

Safeguarding The older source uses rigid age thresholds for suspected neglect or intentional poisoning. Modern assessment instead considers:  Developmental ability Accessibility of the chemical Circumstances of exposure Consistency of the history Previous unexplained injuries or poisonings  Age alone does not establish abuse or neglect.

Occupational Exposure Anhydrous ammonia is an important occupational hazard. Prevention depends on:  Engineering controls Appropriate respiratory/eye/skin protection Safe handling of pressurized systems Emergency decontamination capability  Historical numerical exposure limits should be verified against current occupational standards for the relevant jurisdiction.

Important Modernization of the Older Source  Ammonia is a highly water-soluble alkaline irritant producing direct chemical injury. High-concentration inhalation can cause upper-airway edema, bronchospasm, chemical pneumonitis, acute lung injury, and respiratory failure. Liquefied anhydrous ammonia can cause both chemical and cold-related tissue injury. A normal early chest X-ray does not exclude evolving lung injury. Airway edema can progress; a threatened airway should be managed early. Immediate copious irrigation is the priority for ocular and dermal exposure. Do not delay eye irrigation to measure pH first. Significant ingestion is managed according to caustic-ingestion principles. Absence of visible oral burns does not exclude deeper esophageal injury. Do not induce vomiting. Do not attempt acid–base neutralization. Routine gastric lavage and activated charcoal are inappropriate. Routine forced dilution with large volumes of water or milk is no longer a standard strategy. Bronchoscopy and GI endoscopy are used selectively according to severity and specialist assessment. Bronchodilators are appropriate for bronchospasm. Routine corticosteroids have not been proven to prevent ammonia lung injury. There is no specific antidote. Mixing ammonia with hypochlorite bleach can generate chloramine-type irritant gases. Fixed historical observation periods should be replaced by exposure- and symptom-based assessment.  Key Points  NH₃ + moist tissue → alkaline environment → direct chemical injury. Major targets are the eyes, upper airway, lungs, skin, esophagus, and stomach. Concentrated/anhydrous ammonia can rapidly cause airway edema and severe respiratory injury. Watch for stridor, hoarseness, drooling, wheezing, hypoxemia, and increasing respiratory distress. An initially normal chest radiograph does not rule out evolving lung injury. Eye or skin exposure requires immediate copious irrigation. Significant ingestion is treated as a caustic alkali exposure. Never induce vomiting or attempt chemical neutralization. Activated charcoal has no routine role. Treat bronchospasm supportively and secure a threatened airway early. No specific antidote exists.

. Toxicology – Selective α₁-Adrenergic Antagonists

Core Concept

Selective α₁-adrenergic antagonists are vasodilating medications used mainly for:

• Hypertension
• Benign prostatic hyperplasia (BPH)

Important examples include:

• Prazosin
• Doxazosin
• Terazosin

Other α₁-blockers, particularly those used for BPH, include drugs such as tamsulosin and alfuzosin, although their receptor selectivity and cardiovascular effects differ.

The principal manifestation of overdose is:

Peripheral vasodilation → reduced systemic vascular resistance → hypotension

There is no specific antidote. Treatment is primarily supportive.

Mechanism of Action

α₁ receptors are located on vascular smooth muscle.

Normal α₁ stimulation causes:

Vasoconstriction → ↑ systemic vascular resistance → ↑ blood pressure

α₁ blockade therefore produces:

Vasodilation → ↓ systemic vascular resistance → ↓ blood pressure

In overdose, excessive vasodilation may cause substantial hypotension and impaired organ perfusion.

Effect in Benign Prostatic Hyperplasia

α₁ receptors are also present in smooth muscle of the:

• Prostate
• Bladder neck
• Prostatic urethra

Blocking these receptors decreases smooth-muscle tone and improves urinary flow.

This therapeutic effect is distinct from the vasodilatory mechanism responsible for most overdose toxicity.

Common Agents

Prazosin

A relatively shorter-acting α₁ antagonist.

Used for:

• Hypertension
• Selected urinary symptoms
• Other off-label indications

Doxazosin

Longer acting than prazosin.

Used primarily for:

• Hypertension
• BPH

Terazosin

Also relatively long acting.

Used for:

• Hypertension
• BPH

The longer duration of some agents can result in more prolonged hypotension after substantial overdose.

Other α₁ Blockers

Several newer drugs are used predominantly for BPH, including:

• Tamsulosin
• Alfuzosin
• Silodosin

Some are more selective for α₁ receptor subtypes concentrated in the lower urinary tract and therefore tend to have less systemic blood-pressure effect at therapeutic doses.

Nevertheless, hypotension remains possible in overdose or susceptible patients.

Toxic Dose

There is no reliable universal toxic-dose threshold.

Severity depends on:

• Specific drug
• Amount
• Formulation
• Patient age
• Baseline blood pressure
• Volume status
• Coingestants
• Concurrent cardiovascular medications

Severe isolated poisoning is relatively uncommon, but clinically important hypotension can occur.

Major Toxic Effect – Hypotension

The defining toxicity is:

α₁ blockade → loss of vascular tone → vasodilatory hypotension

Possible manifestations include:

• Lightheadedness
• Weakness
• Dizziness
• Presyncope
• Syncope
• Hypotension
• Shock in severe poisoning

Orthostatic Hypotension

Orthostatic symptoms are especially characteristic.

When the patient stands, normal sympathetic α₁-mediated vasoconstriction is impaired.

This can produce:

• Dizziness
• Blurred vision
• Weakness
• Presyncope
• Syncope

Orthostatic measurements may therefore reveal toxicity that is not obvious while the patient is supine.

First-Dose Phenomenon

Prazosin, doxazosin, and terazosin are historically associated with a first-dose phenomenon.

After starting treatment or substantially increasing the dose, some patients develop pronounced:

• Postural hypotension
• Dizziness
• Syncope

This is a therapeutic adverse effect rather than an overdose-specific syndrome.

Heart Rate

Vasodilation may produce compensatory:

Reflex tachycardia

However, the heart-rate response is variable.

Marked tachycardia may be absent when:

• β-blockers are also present
• Other rate-limiting medications were ingested
• Autonomic responses are impaired
• The patient is severely ill

Bradycardia is possible but is not the classic isolated α₁-blocker finding.

Neurologic Findings

Most neurologic symptoms result from reduced cerebral perfusion.

Possible manifestations include:

• Dizziness
• Lightheadedness
• Weakness
• Fatigue
• Blurred vision
• Syncope

Severe prolonged hypotension can produce:

• Altered mental status
• Cerebral ischemic injury

These findings should prompt evaluation for severe poisoning or an alternative/coexisting cause.

Gastrointestinal Effects

Possible effects include:

• Nausea
• Vomiting
• Abdominal discomfort
• Diarrhea or constipation

These are generally secondary concerns compared with hemodynamic toxicity.

Genitourinary Effects

Chronic therapeutic effects can include:

• Changes in urinary symptoms
• Ejaculatory or other sexual dysfunction

Rarely, α₁ blockade has been associated with priapism.

A prolonged painful erection requires urgent evaluation because ischemic priapism can cause permanent tissue injury.

Older Adults

Older patients may be especially susceptible to:

• Orthostatic hypotension
• Falls
• Syncope
• Injury

Risk may increase with:

• Dehydration
• Diuretics
• Other antihypertensive drugs
• Autonomic dysfunction
• Frailty

Important Drug Interactions

Hypotension may be amplified by other vasodilating or blood-pressure-lowering drugs, including:

• Other antihypertensives
• Nitrates
• PDE-5 inhibitors
• Diuretics
• Alcohol
• Other vasodilators

Rate-limiting medications such as β-blockers can impair compensatory tachycardia.

Therefore, unexpectedly severe hypotension should prompt careful evaluation for coingestion.

PDE-5 Inhibitors

Drugs used for erectile dysfunction can also lower vascular tone.

Combined use with an α₁ blocker can produce clinically important hypotension in susceptible patients.

This interaction is particularly relevant when reviewing medication histories.

Diagnosis

Diagnosis is usually clinical.

Important information includes:

• Exact drug
• Formulation
• Estimated amount
• Time of ingestion
• Other medications
• Baseline cardiovascular disease
• Current symptoms
• Serial blood pressure

Serum concentrations of α₁ antagonists are generally not useful for emergency management.

Physical Examination

Pay particular attention to:

• Blood pressure
• Heart rate
• Mental status
• Peripheral perfusion
• Hydration
• Orthostatic symptoms when safe to assess

Do not force an unstable or markedly symptomatic patient to stand simply to document orthostatic hypotension.

ECG

An ECG is appropriate after clinically significant overdose, particularly when:

• Hypotension is present
• The ingestion was intentional
• Coingestion is possible
• Syncope occurred
• Dysrhythmia or conduction abnormality is suspected

Significant ECG abnormalities should raise suspicion for another drug or additional mechanism.

Laboratory Evaluation

Minor isolated exposures may require little laboratory testing.

In symptomatic patients, useful studies may include:

• Electrolytes
• Creatinine
• Glucose
• CBC when clinically relevant

Other tests depend on the differential diagnosis and coingestants.

Intentional Overdose

In intentional or uncertain overdose, clinicians commonly evaluate for important occult coingestants based on the clinical context.

Acetaminophen testing is particularly relevant in many intentional overdose presentations because early toxicity may be clinically silent.

Testing should be targeted rather than assuming every patient requires the same historical “overdose panel.”

Outdated Adrenal Testing

The older source recommends a dexamethasone suppression test for suspected adrenal insufficiency.

This is incorrect for acute hypotension evaluation.

A dexamethasone suppression test evaluates hypercortisolism, not adrenal failure.

Suspected adrenal crisis is assessed with the appropriate clinical evaluation and cortisol-related testing when feasible, while urgent treatment should not be delayed in a critically ill patient.

Differential Diagnosis

Other toxicologic causes of hypotension include:

• β-blockers
• Calcium-channel blockers
• Tricyclic antidepressants
• Clonidine and other imidazolines
• Nitrates
• Other vasodilators
• Sodium-channel-blocking drugs
• Sedative-hypnotics
• Opioids

Nontoxicologic causes include:

• Sepsis
• Hemorrhage
• Dehydration
• Cardiogenic shock
• Adrenal crisis
• Anaphylaxis
• Autonomic dysfunction

Initial Management

Management centers on:

Airway/breathing assessment → circulation → monitoring → restore perfusion

Most isolated α₁-blocker overdoses require supportive rather than antidote-specific therapy.

IV Fluids

Symptomatic vasodilatory hypotension may respond to appropriate isotonic crystalloid.

However, fluid therapy should be individualized.

Excessive fluid administration can be harmful in patients with:

• Heart failure
• Renal impairment
• Pulmonary edema risk

The goal is adequate perfusion, not administration of a predetermined volume.

Positioning

The historical recommendation for routine Trendelenburg positioning is outdated.

If a patient is hypotensive, keeping them supine and providing appropriate resuscitation is more useful.

Head-down positioning has not demonstrated meaningful sustained hemodynamic benefit and may cause complications.

Vasopressors

If hypotension persists despite appropriate initial resuscitation, vasopressor therapy may be required.

Because α₁ blockade causes vasodilatory shock, modern critical-care practice generally favors norepinephrine for clinically important persistent vasodilatory hypotension.

Management should be titrated to:

• Blood pressure
• Mental status
• Urine output
• Peripheral perfusion
• Other indicators of organ perfusion

Dopamine – Modern Correction

The older source recommends dopamine before norepinephrine.

That is no longer the usual general approach to vasodilatory shock.

Norepinephrine is generally favored because dopamine can produce more:

• Tachycardia
• Dysrhythmias
• Variable hemodynamic effects

Individual circumstances may alter vasopressor selection.

Refractory Shock

If severe hypotension persists, clinicians should reconsider whether the presentation is truly due to isolated α₁ blockade.

Look for:

• β-blocker coingestion
• Calcium-channel blocker coingestion
• Tricyclic antidepressants
• Other vasodilators
• Hemorrhage
• Sepsis
• Cardiogenic shock
• Other causes of refractory hypotension

Advanced hemodynamic support should be guided by the suspected mechanism.

No Specific Antidote

There is no established antidote that directly reverses selective α₁-antagonist poisoning.

Treatment is therefore:

• Supportive monitoring
• Fluids when appropriate
• Vasopressors when required
• Management of coingestants and complications

GI Decontamination – Modern Correction

The older recommendations for ipecac and routine gastric lavage are obsolete.

Ipecac should not be used.

Routine gastric lavage is also inappropriate.

Both can create unnecessary risk and delay supportive care.

Activated Charcoal

A single dose of activated charcoal may occasionally be considered after a substantial recent ingestion when:

• The patient presents sufficiently early
• The drug is expected to be adsorbed
• The airway is safe

It should not be administered routinely or to a patient whose hypotension or altered consciousness creates significant aspiration risk.

Monitoring

Symptomatic patients may require:

• Frequent or continuous blood-pressure monitoring
• Heart-rate monitoring
• ECG monitoring
• Mental-status assessment
• Renal function and urine-output assessment in severe hypotension

Prolonged shock can injure:

• Brain
• Heart
• Kidneys

Early restoration of perfusion reduces this risk.

Duration of Toxicity

Duration varies substantially by agent.

Prazosin generally has a shorter duration than doxazosin or terazosin.

Large ingestions or long-acting agents may therefore produce more prolonged hypotension.

Coingestants can further alter the clinical course.

Observation

The older fixed 6–10-hour and 12–24-hour observation rules should not be applied automatically.

Observation should be based on:

• Specific agent
• Formulation
• Amount
• Time since ingestion
• Symptoms
• Serial blood pressure
• Coingestants
• Patient comorbidities

Patients with persistent hypotension or clinically significant orthostatic symptoms require continued monitoring.

Discharge Principles

Discharge is appropriate when the patient has:

• Stable blood pressure
• No clinically important orthostatic symptoms
• No syncope or evolving neurologic symptoms
• No concerning coingestant effects
• Completed an appropriate observation period for the specific drug

Intentional overdose also requires appropriate safety assessment after medical stabilization.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Management of significant poisoning during pregnancy centers on maintaining adequate:

• Maternal blood pressure
• Oxygenation
• Organ perfusion

Severe maternal hypotension can compromise uteroplacental perfusion, so clinically important poisoning should be treated promptly.

Safeguarding

The older source uses rigid age cutoffs to suggest child abuse or intentional ingestion.

Modern assessment should instead consider:

• Developmental ability
• Medication accessibility
• Caregiver history
• Consistency of the explanation
• Previous poisoning episodes
• Overall safeguarding concerns

Age alone does not establish neglect, abuse, or intentional poisoning.

Important Modernization of the Older Source

• Selective α₁ antagonists primarily cause vasodilatory and orthostatic hypotension.
• Prazosin, doxazosin, and terazosin remain important examples, but several newer BPH-selective α₁ blockers also exist.
• Toxic-dose thresholds are poorly defined; clinical findings are more useful.
• Longer-acting agents may produce more prolonged hypotension.
• Coingestants and other antihypertensive medications can substantially worsen toxicity.
• PDE-5 inhibitors can increase hypotensive effects.
• Serum α₁-blocker concentrations are not useful in routine emergency management.
• Orthostatic testing should not be forced in an unstable patient.
• The historical recommendation for dexamethasone suppression testing in adrenal insufficiency is incorrect.
• Trendelenburg positioning is obsolete as routine shock treatment.
• Norepinephrine is generally preferred over dopamine for persistent vasodilatory shock in modern critical-care practice.
• Ipecac and routine gastric lavage are obsolete.
• Activated charcoal has only a selective role after a recent substantial ingestion with a safe airway.
• There is no specific antidote.
• Fixed observation times should be replaced by agent-specific and symptom-based assessment.
• Historical FDA pregnancy categories are obsolete.

Key Points

• α₁ blockade → vasodilation → ↓ systemic vascular resistance → hypotension.
• The major overdose manifestation is hypotension, particularly orthostatic hypotension.
• Dizziness, weakness, blurred vision, presyncope, and syncope commonly result from reduced cerebral perfusion.
• Reflex tachycardia may occur but can be blunted by coingestants such as β-blockers.
• Prazosin is generally shorter acting; doxazosin and terazosin may produce more prolonged effects.
• Evaluate significant hypotension for cardiovascular coingestants and alternative causes of shock.
• Treatment is mainly supportive, with appropriate fluids and vasopressors for persistent shock.
• No specific antidote exists.
• Do not use ipecac or routine gastric lavage.
• Patients with persistent hypotension, syncope, or significant orthostatic symptoms require continued monitored care.

Toxicology – Ackee Fruit Poisoning

Core Concept

Ackee (Blighia sapida) is a tropical fruit in the soapberry family. Properly ripened and prepared ackee is eaten as food, particularly in Jamaica, but unripe fruit and certain portions of the fruit contain clinically important concentrations of hypoglycin toxins.

Poisoning produces the syndrome historically called Jamaican vomiting sickness.

The hallmark is:

Profound hypoglycemia caused by disruption of fatty-acid oxidation and glucose homeostasis.

Severe poisoning can progress to:

• Recurrent vomiting
• Encephalopathy
• Seizures
• Coma
• Liver injury
• Death

There is no specific antidote. Rapid recognition and correction of hypoglycemia are central to treatment.

Toxic Components

The principal toxins are:

• Hypoglycin A
• Hypoglycin B, which is present particularly in the seeds

Hypoglycin A is especially important because it can be absorbed and metabolically activated.

Toxin concentrations vary markedly with:

• Fruit maturity
• Portion of the fruit
• Preparation

Therefore, there is no reliable single “toxic number” applicable to every exposure.

Which Parts Are Dangerous?

The greatest risk occurs with:

• Unripe ackee
• Seeds
• Improperly prepared fruit

The edible portion is the aril of naturally opened, fully mature fruit, when appropriately prepared.

Importantly, the statement that ackee is simply “poisonous at all times except when fully mature” is an oversimplification.

Toxicity depends on both ripeness and the part consumed.

Mechanism of Toxicity

Hypoglycin A is converted to an active metabolite, methylenecyclopropylacetic acid (MCPA).

MCPA is further converted to metabolites that interfere with enzymes involved in fatty-acid β-oxidation.

The result is a metabolic inability to use fatty acids normally for energy.

Why Hypoglycemia Develops

During fasting or illness, the body normally uses fatty acids for energy while preserving glucose.

Ackee toxins disrupt this process.

Consequences include:

• Impaired fatty-acid oxidation
• Reduced energy production
• Depletion of hepatic glycogen
• Impaired maintenance of blood glucose
• Reduced gluconeogenic capacity

The resulting hypoglycemia can be profound and recurrent.

Metabolic Pattern

Ackee toxicity resembles a metabolic disorder of fatty-acid oxidation.

A useful conceptual pattern is:

Hypoglycemia + impaired fatty-acid oxidation + relatively inadequate ketone production

Therefore, hypoketotic hypoglycemia is an important biochemical clue.

Acyl-CoA Dehydrogenase Inhibition

MCPA metabolites inhibit several acyl-CoA dehydrogenase pathways required for fatty-acid oxidation.

This explains why ackee poisoning can resemble inherited disorders such as multiple acyl-CoA dehydrogenase deficiency.

The metabolic disturbance can persist after the fruit itself has left the gastrointestinal tract.

Typical Clinical Presentation

Early manifestations commonly include:

• Nausea
• Repeated vomiting
• Abdominal discomfort
• Weakness
• Malaise

Neurologic manifestations may follow as glucose falls.

Neurologic Toxicity

Progressive hypoglycemia and metabolic dysfunction can produce:

• Lethargy
• Irritability
• Confusion
• Altered consciousness
• Seizures
• Coma

In severe cases, prolonged neuroglycopenia can cause permanent neurologic injury.

Why Children Are Particularly Vulnerable

Children have:

• Smaller glycogen reserves
• Greater glucose requirements relative to body size
• Less metabolic reserve during fasting and vomiting

Consequently, recurrent vomiting plus inhibition of fatty-acid oxidation can cause rapid metabolic deterioration.

Gastrointestinal Effects

Repeated vomiting is characteristic and gives rise to the historical term:

Jamaican vomiting sickness

Vomiting contributes to:

• Dehydration
• Electrolyte abnormalities
• Reduced carbohydrate intake
• Further depletion of energy stores

This can intensify the underlying metabolic crisis.

Hepatic Effects

Ackee poisoning can produce hepatic injury.

Possible findings include:

• Elevated AST and ALT
• Hepatic dysfunction
• Coagulopathy in severe illness

Liver abnormalities should be monitored in clinically significant poisoning.

Renal Effects

Renal dysfunction may occur secondary to:

• Dehydration
• Hypoperfusion
• Severe systemic illness

Renal function and urine output should therefore be followed in severe poisoning.

Acid–Base Abnormalities

Severe illness may be associated with metabolic acidosis.

Potential contributors include:

• Tissue hypoperfusion
• Seizures
• Metabolic dysfunction
• Dehydration

Acid–base abnormalities should be interpreted in the context of the entire clinical syndrome.

Diagnosis

Diagnosis is usually clinical and based on:

• History of ackee ingestion
• Fruit maturity/preparation
• Recurrent vomiting
• Hypoglycemia
• Neurologic deterioration
• Compatible metabolic abnormalities

The exact amount consumed is often less informative because toxin concentrations vary substantially between fruits.

Essential Laboratory Evaluation

In a symptomatic patient, important tests include:

• Bedside glucose immediately
• Serial serum glucose
• Electrolytes
• Bicarbonate
• Renal function
• Liver tests

Depending on severity, additional testing may include:

• Blood gas
• Lactate
• Ketones
• INR
• CBC
• CK after prolonged seizures
• Other metabolic studies

Glucose Must Be Checked Early

This is the most important immediate diagnostic step.

A patient with suspected ackee poisoning and:

• Vomiting
• Lethargy
• Confusion
• Seizure
• Coma

should have glucose assessed promptly.

Treatment of dangerous hypoglycemia should not be delayed while waiting for laboratory confirmation.

Ketones

Because fatty-acid oxidation is impaired, ketone production may be inappropriately low relative to the severity of hypoglycemia.

Thus:

Severe hypoglycemia + unexpectedly low ketones

supports a fatty-acid oxidation problem.

This pattern is not specific to ackee poisoning but can strengthen the diagnosis in the appropriate exposure setting.

Specialized Testing

Specialized metabolic testing can sometimes identify metabolites associated with hypoglycin exposure.

Such testing may be useful for:

• Confirming outbreaks
• Public-health investigation
• Uncertain diagnoses

It is generally not required before emergency treatment begins.

Differential Diagnosis

Important alternatives include:

• Salicylate poisoning
• Acetaminophen-associated hepatic failure
• Sepsis
• Gastroenteritis with starvation
• Insulin or sulfonylurea exposure
• Severe liver disease
• Adrenal insufficiency
• Inborn errors of fatty-acid oxidation
• Other causes of hypoglycemic encephalopathy

In a child, unexplained hypoglycemia should not automatically be attributed to the fruit without considering other dangerous causes.

Treatment Priorities

Management centers on:

Airway and circulation → immediate glucose assessment/correction → control seizures → restore fluids/electrolytes → prevent recurrent hypoglycemia

There is no toxin-specific antidote.

Dextrose

Clinically significant hypoglycemia requires prompt glucose replacement.

After initial correction, glucose can fall again because the underlying metabolic defect may persist.

Therefore:

One normal glucose measurement after treatment does not mean the poisoning has resolved.

Serial monitoring is essential.

Recurrent Hypoglycemia

Repeated or continuous glucose support may be required until the patient can reliably maintain normal glucose metabolism.

Management should be guided by:

• Serial glucose
• Mental status
• Ability to tolerate nutrition
• Electrolytes
• Overall metabolic recovery

Exact glucose regimens should follow current age-appropriate emergency and pediatric protocols.

Nutrition

Once clinically appropriate, provision of carbohydrate helps reduce dependence on fatty-acid oxidation.

Prolonged fasting should be avoided during the acute metabolic disturbance.

Patients with significant vomiting may initially require parenteral glucose support.

Seizures

Seizures may result primarily from:

• Severe hypoglycemia
• Metabolic disturbance

Therefore:

Correct glucose immediately while also treating ongoing seizures.

Benzodiazepines are first-line conventional therapy for persistent toxicologic seizures.

Correction of the underlying hypoglycemia is essential because anticonvulsants alone do not address the cause.

Fluids and Electrolytes

Repeated vomiting can produce substantial volume depletion.

Management may require:

• Appropriate isotonic fluid replacement
• Electrolyte correction
• Serial renal assessment

Fluid therapy should be individualized to clinical volume status.

No Specific Antidote

There is no established antidote that directly neutralizes hypoglycin or its active metabolites.

Treatment remains primarily:

• Glucose support
• Hydration
• Electrolyte management
• Seizure control
• Organ-supportive care

GI Decontamination – Modern Correction

The historical source recommends ipecac and gastric lavage.

These practices are obsolete.

Ipecac should not be used.

Ackee poisoning already commonly causes severe vomiting, and additional induced vomiting can:

• Worsen dehydration
• Increase aspiration risk
• Delay glucose treatment

Routine gastric lavage is also inappropriate.

Activated Charcoal

Activated charcoal does not have a well-established routine role in ackee poisoning.

Management priorities are rapid recognition of hypoglycemia and supportive care.

Charcoal should not delay:

• Glucose correction
• Airway management
• Seizure treatment
• Fluid resuscitation

Monitoring

Symptomatic patients should have serial assessment of:

• Blood glucose
• Mental status
• Heart rate and blood pressure
• Respiratory status
• Electrolytes
• Renal function
• Hepatic function

Severe cases may additionally require:

• Continuous cardiorespiratory monitoring
• Acid–base assessment
• Lactate
• INR
• Seizure monitoring

Observation

The older fixed 6-hour discharge rule is too simplistic.

Observation should account for:

• Ripeness and portion of fruit consumed
• Amount and timing
• Symptoms
• Serial glucose
• Ability to eat
• Vomiting
• Neurologic status
• Laboratory abnormalities

Because hypoglycemia can recur, a patient should not be discharged solely because one glucose value normalized after treatment.

Admission

Hospital management is appropriate when there is:

• Hypoglycemia
• Recurrent vomiting
• Significant dehydration
• Altered mental status
• Seizures
• Hepatic injury
• Metabolic acidosis
• Inability to maintain glucose orally
• Other evidence of significant systemic toxicity

Severe cases may require intensive care.

Prognosis

Mild poisoning recognized early can resolve completely with appropriate supportive care.

Poor outcomes are mainly associated with:

• Profound or prolonged hypoglycemia
• Recurrent seizures
• Coma
• Severe metabolic derangement
• Delayed recognition and treatment

Historical mortality estimates from older outbreaks should not automatically be applied to patients receiving contemporary emergency and intensive care.

Safeguarding Considerations

The historical source suggests automatically considering neglect or abuse according to rigid age cutoffs.

That approach is outdated.

In children, safeguarding assessment should instead consider:

• Developmental ability
• Access to the fruit
• Caregiver history
• Preparation practices
• Consistency of the history
• Previous unexplained poisonings or injuries

Accidental poisoning should not be labeled abuse solely on the basis of age.

Prevention

The key preventive principle is:

Do not consume unripe or spontaneously unopened ackee fruit or the seeds.

Food safety depends on appropriate harvesting and preparation of the edible portion.

Commercial food regulation is important because toxin concentrations are strongly influenced by fruit maturity and processing.

Important Modernization of the Older Source

• The preferred spelling is commonly ackee, from Blighia sapida.
• Hypoglycin A is the major systemic toxin associated with the edible aril when inadequately ripened/prepared.
• Toxicity varies with fruit maturity and the portion consumed, so there is no single reliable toxic dose.
• Hypoglycin A is metabolized to MCPA, whose metabolites inhibit fatty-acid oxidation.
• The characteristic metabolic consequence is hypoketotic hypoglycemia.
• Recurrent vomiting worsens dehydration and energy depletion.
• Severe hypoglycemia causes lethargy, seizures, coma, and potentially permanent neurologic injury.
• Check bedside glucose immediately in any symptomatic suspected exposure.
• A normal glucose after initial correction does not exclude recurrent hypoglycemia.
• Treatment centers on sustained glucose availability and supportive care.
• There is no specific antidote.
• Ipecac and routine gastric lavage are obsolete.
• Activated charcoal does not have an established routine role.
• Fixed historical observation periods should be replaced by serial clinical and glucose assessment.
• Historical mortality figures should be interpreted cautiously.
• Child safeguarding assessment should be based on the complete circumstances rather than rigid age cutoffs.

Key Points

• Unripe/improperly prepared ackee → hypoglycin exposure.
• Hypoglycin A → MCPA metabolites → inhibition of fatty-acid β-oxidation.
• The hallmark is hypoketotic hypoglycemia.
• Typical presentation: recurrent vomiting → lethargy → seizures/coma in severe cases.
• Children can deteriorate rapidly because of limited metabolic reserves.
• Check and correct glucose immediately.
• Hypoglycemia may recur, requiring continued glucose support and serial monitoring.
• Correct dehydration and electrolyte abnormalities and treat seizures promptly.
• No specific antidote exists.
• Do not induce vomiting or routinely perform gastric lavage.

Toxicology – Acrylamide

Core Concept

Acrylamide (C₃H₅NO) is a water-soluble vinyl monomer used mainly to manufacture polyacrylamide and in several industrial processes.

The key toxicologic distinction is:

Acrylamide monomer = neurotoxic

whereas

Polymerized polyacrylamide = substantially less toxic

Toxicity from commercial polyacrylamide products is primarily a concern when residual unpolymerized acrylamide monomer is present.

The characteristic effect of repeated exposure is a progressive peripheral sensorimotor neuropathy, although substantial acute exposure can also cause severe CNS toxicity.

There is no specific antidote.

Sources and Uses

Acrylamide is used in:

• Polyacrylamide production
• Water and wastewater treatment processes
• Mining
• Tunneling and grouting
• Paper and textile industries
• Dye and chemical synthesis
• Laboratory electrophoresis gels

Occupational exposure to the monomer is much more toxicologically important than contact with fully polymerized material.

Acrylamide in Food

Acrylamide can also form naturally during high-temperature cooking of certain carbohydrate-rich foods through the Maillard reaction, particularly when foods are:

• Fried
• Roasted
• Baked

Examples include some potato products, baked goods, and roasted foods.

These dietary exposures are fundamentally different from the much larger occupational or accidental exposures associated with acute neurologic poisoning.

Routes of Exposure

Acrylamide can enter the body through:

• Skin
• Inhalation
• Ingestion

Dermal absorption is particularly important in occupational exposure.

Repeated handling of concentrated acrylamide monomer without adequate protection can therefore produce systemic neurotoxicity even without ingestion.

Mechanism of Neurotoxicity

Acrylamide affects both the central and peripheral nervous systems.

Repeated exposure particularly damages long axons, producing a pattern historically described as:

“Dying-back” axonopathy

This means degeneration begins in the distal portion of long axons and progresses proximally.

Consequently, the longest peripheral nerves are often affected first.

Peripheral Neuropathy Pattern

The typical chronic pattern is:

Distal sensory symptoms → distal weakness → impaired reflexes → gait and coordination problems

Hands and feet are commonly affected early.

Possible symptoms include:

• Numbness
• Tingling
• Paresthesias
• Burning sensations
• Weakness
• Loss of dexterity
• Difficulty walking

Glycidamide

Acrylamide can be metabolized through CYP2E1 to glycidamide, a reactive epoxide metabolite.

Glycidamide can interact with:

• DNA
• Proteins
• Other cellular macromolecules

This pathway is particularly relevant to the genotoxic and carcinogenic concerns associated with acrylamide exposure.

Neurotoxicity also involves direct effects of acrylamide on neuronal proteins and axonal function.

Acute High-Level Exposure

Large acute exposures may initially produce CNS manifestations such as:

• Agitation
• Confusion
• Disorientation
• Tremor
• Ataxia
• Dysarthria
• Hallucinations
• Somnolence
• Seizures

Severe poisoning can progress to:

• Encephalopathy
• Cardiovascular instability
• Respiratory compromise
• Coma

Peripheral neuropathy may emerge after the acute CNS manifestations.

Chronic Exposure

Most recognized occupational toxicity develops after repeated exposure over weeks or longer.

Early findings can include:

• Tingling in hands or feet
• Distal numbness
• Weak grip
• Dropping objects
• Difficulty with fine motor tasks
• Unsteady walking
• Increased stumbling

These subtle occupational clues may precede obvious neurologic disability.

Motor Findings

Motor neuropathy can cause:

• Distal limb weakness
• Weak wrist or finger movements
• Ankle weakness
• Foot drop in advanced disease
• Difficulty walking
• Reduced coordination

Longer axons are generally affected more prominently.

Reflex Changes

Peripheral axonal injury may produce:

• Reduced deep tendon reflexes
• Absent ankle reflexes
• Other hyporeflexic findings

Reflex abnormalities should be interpreted alongside sensory and motor findings.

Autonomic Dysfunction

Autonomic nerves may also be affected.

Possible findings include:

• Abnormal sweating
• Urinary dysfunction
• Constipation
• Other autonomic disturbances

Historically, excessive sweating of the hands and feet has been described as an occupational clue.

Cerebellar and Central Findings

Significant exposure may produce:

• Tremor
• Ataxia
• Gait instability
• Dysarthria
• Impaired coordination

This combination of central and peripheral findings can help distinguish severe acrylamide neurotoxicity from a purely peripheral neuropathy.

Dermal Findings

Direct contact with acrylamide monomer can produce:

• Erythema
• Irritation
• Peeling or desquamation
• Dermatitis

Skin abnormalities in a worker handling acrylamide should also prompt assessment for systemic exposure and neurologic symptoms.

Ocular and Respiratory Irritation

Exposure can cause:

• Eye irritation
• Throat irritation
• Cough

These findings are generally less characteristic than the neurologic syndrome.

Persistent respiratory symptoms should prompt evaluation for alternative or additional workplace exposures.

Gastrointestinal and Systemic Effects

Reported manifestations after substantial exposure include:

• Nausea
• Reduced appetite
• Constipation
• Weight loss

Hepatic abnormalities have also been reported after significant poisoning.

Pancreatic injury has been described rarely but is not a defining feature.

Hematologic Effects

Thrombocytopenia and other laboratory abnormalities have occasionally been reported after substantial exposure.

These are not sufficiently characteristic to diagnose acrylamide poisoning.

Carcinogenicity

The older source describes acrylamide as a “probable human carcinogen.”

The key study point is that acrylamide has genotoxic and carcinogenic potential, particularly through its glycidamide metabolite.

This is mainly relevant to long-term exposure and risk reduction, rather than the immediate management of acute poisoning.

Reproductive Toxicity

Animal studies have demonstrated reproductive and developmental effects, including effects on male germ cells at sufficient exposures.

Human reproductive-risk assessment is less straightforward.

The practical approach is to minimize unnecessary occupational exposure, especially to concentrated acrylamide monomer.

Diagnosis

There is no single bedside laboratory test that confirms clinically important acrylamide neurotoxicity.

Diagnosis relies primarily on:

• Exposure history
• Occupational history
• Neurologic examination
• Pattern of symptoms
• Electrodiagnostic testing when appropriate
• Exclusion of alternative neuropathies

Occupational History Is Essential

Ask about:

• Exact job tasks
• Acrylamide monomer handling
• Duration and frequency of exposure
• Skin contact
• Ventilation
• Personal protective equipment
• Spills
• Similar symptoms among coworkers

The diagnosis can easily be missed if occupational exposure is not specifically investigated.

Laboratory Evaluation

Routine laboratory testing may be unnecessary after a minor exposure in an asymptomatic person.

For substantial or symptomatic exposure, testing can include:

• CBC
• Electrolytes
• Glucose
• Renal function
• Hepatic tests

Other investigations should be guided by symptoms and differential diagnosis.

Acrylamide Concentrations

Measuring acrylamide itself is generally not useful for acute bedside management.

Specialized biomarkers or exposure measurements may have roles in:

• Occupational medicine
• Epidemiologic studies
• Exposure assessment

but they do not replace clinical evaluation of suspected neurotoxicity.

Nerve Conduction Studies and EMG

Electrodiagnostic testing can help document:

• Peripheral nerve dysfunction
• Axonal injury
• Distribution of neuropathy
• Severity
• Evolution or recovery over time

Serial testing may be useful when substantial neuropathy is present.

Lumbar Puncture

The historical source suggests CSF protein may be increased.

Lumbar puncture is not routinely required to diagnose acrylamide toxicity.

It is more useful when another neurologic disorder is being considered, such as:

• Guillain–Barré syndrome
• Inflammatory neuropathy
• CNS infection

EEG

EEG is not routinely necessary.

It may be appropriate when there is:

• Persistent altered mental status
• Recurrent seizures
• Concern for nonconvulsive status epilepticus

Differential Diagnosis

Other causes of peripheral neuropathy include:

• Arsenic
• Thallium
• Lead
• Mercury
• n-Hexane
• Carbon disulfide
• Organophosphate-induced delayed neuropathy
• Alcohol-related neuropathy
• Diabetes
• Vitamin deficiencies
• Renal disease
• Immune-mediated neuropathies

The time course and occupational history help distinguish these conditions.

Initial Management

The fundamental treatment is:

Stop exposure → decontaminate → supportive care → monitor neurologic function

There is no antidote that reverses acrylamide already bound to or affecting neuronal targets.

Dermal Decontamination

After significant skin exposure:

• Remove contaminated clothing.
• Prevent continued occupational exposure.
• Wash exposed skin thoroughly.

Because dermal absorption can contribute substantially to systemic exposure, early removal of contamination is important.

Ocular Exposure

Eye exposure requires prompt irrigation.

Persistent:

• Pain
• Redness
• Photophobia
• Visual disturbance

should prompt further ocular evaluation.

Inhalational Exposure

Move the patient away from the source and assess:

• Airway
• Breathing
• Oxygenation

Supplemental oxygen is used when clinically indicated rather than automatically for every minor exposure.

GI Decontamination

The historical recommendation for routine gastric lavage after large ingestion is outdated.

Routine gastric lavage is not recommended.

Activated charcoal may occasionally be considered after a substantial recent ingestion if:

• The patient presents early
• The substance is expected to be adsorbed
• The airway is safe

but evidence specific to acrylamide poisoning is limited.

Do not induce vomiting.

No Specific Antidote

There is no established antidote for acrylamide poisoning.

Management centers on:

• Exposure termination
• Supportive care
• Seizure management
• Neurologic monitoring
• Rehabilitation when neuropathy develops

Seizures

Acute severe poisoning may produce seizures.

Benzodiazepines are first-line treatment for toxicant-induced seizures.

Persistent seizures require escalation according to modern status-epilepticus/toxicologic protocols.

Important Correction – Phenytoin

The older source suggests phenytoin as an additional anticonvulsant.

For many toxicant-induced seizures, phenytoin is less useful because it does not address the common toxicologic mechanisms causing seizures.

Persistent toxicologic seizures are generally managed with agents such as:

• Additional benzodiazepine therapy
• Phenobarbital
• Other appropriate anesthetic/critical-care anticonvulsant strategies when necessary

Treatment depends on the clinical situation.

Neuromuscular Blockade Does Not Treat the Seizure

Paralysis may sometimes be necessary during advanced airway or critical-care management, but:

Neuromuscular blockade stops visible muscle movement; it does not stop electrical seizure activity in the brain.

If paralysis is used, adequate anticonvulsant therapy and appropriate EEG monitoring may be necessary.

Neuropathy Management

Once peripheral neuropathy develops, treatment is largely supportive.

Management can include:

• Removal from further exposure
• Physical therapy
• Occupational therapy
• Gait assessment
• Fall prevention
• Management of neuropathic symptoms
• Neurology and occupational-medicine follow-up

Recovery

Recovery may take:

• Weeks
• Months
• Occasionally longer

Peripheral nerves can recover gradually after exposure stops.

However, severe axonal injury may leave residual:

• Sensory loss
• Weakness
• Gait impairment
• Coordination difficulties

Repeat Exposure

Further exposure during recovery may worsen neurologic injury or interfere with recovery.

Return to work should therefore be considered with:

• Occupational medicine
• Industrial hygiene
• Exposure-control assessment

rather than simply returning the patient to the same uncontrolled environment.

Observation After Acute Exposure

There is no universally validated observation duration.

Monitoring should depend on:

• Amount and concentration
• Route
• Duration
• Neurologic findings
• Presence of seizures or encephalopathy
• Coexposures

A fixed historical 6–12-hour rule should not replace individualized assessment.

Occupational Exposure Limits

The numerical workplace limits in older references may no longer reflect current standards.

Current exposure limits should be checked through the applicable occupational-health authority for the relevant jurisdiction.

The key prevention principle is to minimize exposure to unpolymerized acrylamide monomer, particularly through skin contact.

Pregnancy and Reproductive Considerations

Animal data demonstrate reproductive and developmental toxicity at sufficient exposures, but these findings cannot be translated directly into a simple prediction of human fetal risk.

After significant exposure during pregnancy:

• Stop further exposure.
• Treat maternal toxicity appropriately.
• Obtain occupational/toxicology assessment.
• Consider obstetric evaluation according to exposure severity.

Maternal stabilization remains the priority in severe poisoning.

Important Modernization of the Older Source

• Acrylamide monomer is neurotoxic; fully polymerized polyacrylamide is much less toxic.
• Residual monomer contamination accounts for much of the concern with polymer products.
• Dermal absorption is an important occupational route.
• Chronic exposure classically causes a distal sensorimotor axonal polyneuropathy with possible autonomic and CNS involvement.
• Severe acute exposure can cause encephalopathy, ataxia, tremor, and seizures.
• Acrylamide can be metabolized to the reactive epoxide glycidamide, which contributes to genotoxicity.
• Dietary acrylamide exposure from high-temperature cooking should not be equated with the high-level occupational exposures responsible for classic acute neurotoxicity.
• Diagnosis is primarily clinical and occupational; routine serum acrylamide measurement is not useful for emergency management.
• EMG and nerve-conduction studies can document significant peripheral neuropathy.
• Lumbar puncture is not routinely required.
• There is no specific antidote.
• Routine gastric lavage is obsolete.
• Activated charcoal has, at most, a selective role after a recent substantial ingestion.
• Benzodiazepines are first-line for acute toxicant-induced seizures.
• Phenytoin is generally not a preferred treatment for many toxin-mediated seizures.
• Neuromuscular paralysis does not terminate cerebral seizure activity.
• Recovery from neuropathy can take months and may be incomplete after severe exposure.
• Prevention of repeat exposure is a central component of treatment.
• Historical workplace exposure limits should be verified against current occupational regulations.

Key Points

• Acrylamide monomer → neurotoxicity; polyacrylamide polymer → much lower toxicity.
• Repeated occupational exposure classically causes dying-back distal axonal neuropathy.
• Early clues include numbness, paresthesias, weak grip, dropping objects, and gait instability.
• Severe acute exposure can produce confusion, tremor, ataxia, seizures, and encephalopathy.
• Dermal absorption is an important route.
• Glycidamide contributes to acrylamide’s genotoxic and carcinogenic potential.
• Diagnosis depends heavily on a detailed occupational and exposure history.
• Nerve-conduction studies/EMG can help characterize significant neuropathy.
• Treatment is removal from exposure, decontamination, supportive care, and neurologic rehabilitation.
• No specific antidote exists.

Toxicology – Acrolein

Core Concept

Acrolein (CH₂=CH–CHO) is a highly reactive, volatile aldehyde and powerful mucosal, ocular, dermal, and respiratory irritant.

It is also called:

• Acrylaldehyde
• 2-propenal
• Propenal

Acrolein is encountered in some industrial processes and is also generated during combustion and thermal decomposition of organic material, making it an important component of smoke.

The major toxicologic principle is:

Acrolein → direct local tissue injury rather than systemic metabolic poisoning.

There is no specific antidote. Treatment consists primarily of rapid removal from exposure, decontamination, and supportive respiratory/ocular/dermal care.

Sources and Uses

Acrolein has been used in:

• Chemical manufacturing
• Production of chemical intermediates
• Biocide and algicide applications
• Industrial water systems
• Selected agricultural applications

It can also form during combustion of:

• Wood
• Tobacco
• Plastics
• Petroleum products
• Other organic materials

Thus, acrolein exposure can occur as part of a mixed smoke inhalation injury rather than from isolated industrial exposure.

Routes of Exposure

Important routes are:

• Inhalation
• Ocular contact
• Dermal contact
• Ingestion, although less common

Because acrolein is volatile and intensely irritating, inhalation is particularly important.

Mechanism of Toxicity

Acrolein is a highly electrophilic α,β-unsaturated aldehyde.

It reacts readily with cellular nucleophiles, including:

• Sulfhydryl-containing molecules
• Glutathione
• Proteins
• Other cellular macromolecules

This produces:

• Oxidative stress
• Depletion of protective thiols
• Membrane injury
• Inflammation
• Direct epithelial damage

The tissues receiving the greatest direct exposure are therefore most affected.

Primary Target Organs

The main targets are:

• Eyes
• Nose
• Oropharynx
• Airways
• Lungs
• Skin

Severe inhalational exposure can produce significant lower-airway and pulmonary injury.

Irritant vs “Caustic” Injury

The historical source describes acrolein primarily as a caustic.

A more useful modern description is:

Acrolein is a highly reactive irritant capable of producing direct chemical tissue injury.

High-concentration liquid contact can cause chemical burns, while vapor exposure predominantly produces severe irritation and inflammatory airway injury.

Inhalation Toxicity

Early manifestations may include:

• Burning of the nose or throat
• Rhinorrhea
• Cough
• Chest irritation
• Dyspnea
• Tachypnea

More substantial exposure can cause:

• Bronchospasm
• Airway inflammation
• Hypoxemia
• Chemical pneumonitis
• Acute lung injury
• Noncardiogenic pulmonary edema

Bronchospasm

Acrolein can trigger significant bronchial irritation and constriction.

Patients with pre-existing reactive airway disease may experience particularly prominent:

• Wheezing
• Chest tightness
• Cough
• Dyspnea

Treatment is supportive, with inhaled bronchodilator therapy when bronchospasm is clinically present.

Delayed Pulmonary Injury

An important concern after significant inhalation is that pulmonary injury may evolve after the initial exposure.

Possible delayed findings include:

• Increasing cough
• Worsening dyspnea
• Hypoxemia
• Crackles
• Pulmonary infiltrates
• Acute lung injury

The older literature describes pulmonary edema appearing as late as 24–72 hours.

In modern practice, observation is individualized according to:

• Exposure intensity
• Symptoms
• Oxygenation
• Respiratory examination
• Clinical trajectory

A rigid observation period should not replace clinical assessment.

Noncardiogenic Pulmonary Edema

Severe direct pulmonary injury can increase alveolar-capillary permeability.

This may produce:

Chemical injury → inflammatory endothelial/epithelial damage → capillary leak → pulmonary edema

This differs from pulmonary edema caused primarily by left ventricular failure.

Management is supportive and may require escalating respiratory support.

Smoke Inhalation

Acrolein may be one of several toxicants present in smoke.

Other simultaneous hazards can include:

• Carbon monoxide
• Cyanide
• Particulate matter
• Other aldehydes
• Irritant gases

Therefore, a patient exposed to fire smoke should not have all symptoms attributed to acrolein alone.

Ocular Exposure

Acrolein vapor can rapidly cause:

• Burning
• Lacrimation
• Conjunctival irritation
• Redness
• Blepharospasm

Liquid splash or substantial exposure can produce:

• Corneal epithelial injury
• Chemical keratitis
• More severe ocular burns

Ocular Management

The immediate priority is prompt irrigation.

After irrigation, persistent:

• Pain
• Photophobia
• Visual disturbance
• Abnormal ocular examination

should prompt further ophthalmic evaluation.

A slit-lamp examination with fluorescein can help identify corneal epithelial injury.

Irrigation should not be delayed merely to perform diagnostic testing first.

Dermal Exposure

Skin exposure can produce:

• Burning
• Erythema
• Irritant dermatitis
• Pain
• Chemical burns after substantial contact

Management begins with:

• Removal of contaminated clothing
• Prompt irrigation
• Appropriate cleansing
• Assessment of resulting chemical injury

Significant burns are managed according to standard burn-care principles.

Ingestion

Ingestion is less common but can produce direct irritation of the gastrointestinal tract.

Possible manifestations include:

• Oral or pharyngeal burning
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

Severe ingestion should be approached as a potentially significant chemical exposure, with attention to airway and GI injury.

Do Not Induce Vomiting

Vomiting should not be induced after acrolein ingestion.

Induced emesis can:

• Re-expose the esophagus and pharynx
• Increase aspiration risk
• Worsen pulmonary injury

Ipecac has no modern role.

Activated Charcoal

Activated charcoal is not a routine treatment for acrolein exposure.

Because toxicity is dominated by rapid local chemical injury, decontamination and supportive care are more important than attempting GI adsorption.

Vital Signs

Symptomatic exposure may produce:

• Tachycardia
• Tachypnea
• Elevated blood pressure related to distress or sympathetic activation

Severe pulmonary injury can instead lead to:

• Hypoxemia
• Respiratory failure
• Hemodynamic instability

Vital-sign abnormalities are nonspecific and should be interpreted with the overall clinical picture.

Laboratory Evaluation

There is no routinely useful blood test that specifically confirms acrolein poisoning.

Mild exposures may require no laboratory investigation.

Testing in significant inhalational injury can include:

• Pulse oximetry
• Blood gas when respiratory compromise is suspected
• Electrolytes and other general laboratory studies when clinically indicated

Evaluation should be driven by severity rather than performed automatically.

Chest Imaging

Chest radiography can help assess patients with:

• Persistent respiratory symptoms
• Hypoxemia
• Abnormal lung examination
• Suspected pulmonary edema or pneumonitis

However:

An initially normal chest radiograph does not necessarily exclude evolving inhalational lung injury.

Clinical reassessment remains important.

Pulmonary Function Testing

Formal pulmonary function testing is generally not an emergency diagnostic requirement.

It may have a role in follow-up when persistent respiratory symptoms or occupational lung injury are suspected.

Differential Diagnosis

Other inhaled irritants can produce a similar syndrome, including:

• Chlorine
• Chloramines
• Ammonia
• Sulfur dioxide
• Nitrogen oxides
• Phosgene
• Formaldehyde
• Smoke mixtures

Exposure history and the industrial or fire environment are often more informative than the clinical syndrome alone.

Initial Management of Inhalation

The priorities are:

• Remove the patient from the exposure
• Prevent further exposure of rescuers
• Assess airway and breathing
• Provide supplemental oxygen when clinically indicated
• Monitor for bronchospasm and evolving pulmonary injury

Severe respiratory distress requires escalation of airway and ventilatory support.

Oxygen

The older source recommends 100% oxygen for all exposures.

Modern management is more individualized.

Supplemental oxygen is clearly appropriate for:

• Hypoxemia
• Significant respiratory distress
• Severe smoke exposure
• Suspected carbon monoxide coexposure

Isolated minor acrolein irritation in a normally oxygenated patient does not inherently require prolonged maximal-concentration oxygen.

Bronchodilators

Patients with clinically significant bronchospasm may benefit from an inhaled β₂-agonist bronchodilator.

Treatment should be guided by:

• Wheezing
• Airflow limitation
• Respiratory distress
• Response to therapy

Historical fixed dosing regimens should not replace current age-appropriate respiratory protocols.

Corticosteroids

Routine corticosteroid administration solely to prevent delayed acrolein lung injury is not well established.

They should not be given automatically after every exposure.

Their use may be considered for another established indication, such as a significant exacerbation of underlying reactive airway disease.

Antibiotics

Prophylactic antibiotics are not routinely indicated for uncomplicated chemical pneumonitis.

Antibiotics are reserved for situations in which bacterial infection is suspected or demonstrated.

Severe Respiratory Failure

If acute lung injury progresses, management follows standard supportive principles and may include:

• Supplemental oxygen
• Noninvasive respiratory support in appropriately selected patients
• Endotracheal intubation when necessary
• Lung-protective mechanical ventilation

There is no acrolein-specific antidotal therapy.

Decontamination

Inhalation

Move the patient to uncontaminated air and assess respiratory status.

Skin

Remove contaminated clothing and irrigate exposed skin thoroughly.

Eyes

Begin immediate irrigation and continue according to chemical-eye-injury principles.

The most important principle is:

Do not delay irrigation while searching for a specific neutralizing chemical.

Do Not Chemically Neutralize

Attempting to neutralize a reactive chemical on the skin or eye with another chemical can:

• Generate heat
• Produce additional tissue injury
• Delay irrigation

Copious irrigation is preferred.

No Specific Antidote

There is no established antidote that directly neutralizes systemic acrolein toxicity.

Treatment remains:

Exposure termination + decontamination + respiratory/ocular/dermal supportive care

Observation

Patients with only minor transient irritation who become completely asymptomatic may require relatively short observation.

Longer monitoring is appropriate when there is:

• Significant inhalation
• Persistent cough
• Wheezing
• Dyspnea
• Hypoxemia
• Abnormal lung examination
• Abnormal imaging
• Significant ocular or dermal injury
• Mixed smoke exposure

The historical universal 4–6-hour discharge rule should not be applied mechanically.

Discharge Considerations

Before discharge after an inhalational exposure, the patient should have:

• Stable respiratory status
• No evolving dyspnea
• Acceptable oxygenation
• No concerning progression on examination
• Appropriate follow-up when needed

Patients should seek urgent reassessment if respiratory symptoms develop or worsen after discharge.

Long-Term Effects

Most mild exposures resolve without permanent injury.

Substantial respiratory exposure can occasionally result in persistent:

• Airway hyperreactivity
• Respiratory symptoms
• Reduced pulmonary function

Follow-up may therefore be appropriate after severe occupational or inhalational injury.

Pregnancy

Historical animal reproductive-toxicity findings do not provide a simple prediction of human pregnancy risk.

Management of an exposed pregnant patient should focus on:

• Stopping exposure
• Preventing maternal hypoxemia
• Treating significant respiratory injury
• Appropriate obstetric assessment after substantial exposure

Maternal stabilization remains the priority.

Occupational Exposure Limits

The numerical workplace limits in older references may no longer reflect current standards.

Occupational limits should be checked against current guidance for the relevant:

• Country
• Regulatory agency
• Workplace
• Exposure duration

Historical concentration values should therefore not be used as universal current safety thresholds.

Important Modernization of the Older Source

• Acrolein is a highly reactive α,β-unsaturated aldehyde that primarily causes direct local tissue and oxidative injury.
• Major target tissues are the eyes, mucous membranes, skin, airways, and lungs.
• Acrolein is also an important irritant component of combustion smoke.
• Significant inhalation can cause bronchospasm, chemical pneumonitis, acute lung injury, and noncardiogenic pulmonary edema.
• Respiratory deterioration can be delayed, but observation duration should be individualized rather than automatically extending every patient to 24–72 hours.
• An initially normal chest radiograph does not exclude evolving pulmonary injury.
• Formal pulmonary function testing is not routinely required during acute emergency evaluation.
• Immediate irrigation is the priority for ocular and dermal exposure.
• Do not attempt chemical neutralization of skin or eye exposure.
• Ipecac and induced vomiting have no role.
• Activated charcoal is not routinely useful.
• Oxygen therapy should be guided by respiratory status and possible coexposures rather than automatically given at maximal concentration after every minor isolated exposure.
• Bronchodilators are appropriate for clinically important bronchospasm.
• Routine prophylactic corticosteroids and antibiotics are not established treatments.
• There is no specific antidote.
• Mixed smoke exposure should prompt evaluation for other toxicants, especially carbon monoxide and potentially cyanide.
• Pregnancy management centers on preventing maternal hypoxemia and treating maternal toxicity.
• Historical occupational exposure limits should be verified against current jurisdiction-specific standards.

Key Points

• Acrolein → direct reactive/oxidative tissue injury.
• The major organs affected are the eyes, skin, respiratory mucosa, and lungs.
• Inhalation may cause cough, bronchospasm, chemical pneumonitis, and delayed acute lung injury.
• Acrolein is also produced during combustion, so smoke exposure may involve multiple toxicants.
• Immediate removal from exposure and irrigation are the main decontamination measures.
• An initially normal chest X-ray does not completely exclude evolving lung injury.
• Treat bronchospasm with appropriate inhaled bronchodilator therapy and respiratory failure with standard supportive ventilation.
• No specific antidote exists.
• Do not induce vomiting, and do not routinely use activated charcoal.
• Significant respiratory exposure requires continued observation for evolving pulmonary toxicity.

Toxicology – Acetonitrile and Other Aliphatic Nitriles

Core Concept

Aliphatic nitriles are organic compounds containing a –C≡N (nitrile) group. Important examples include:

• Acetonitrile
• Acrylonitrile
• Propionitrile
• Butyronitrile
• Succinonitrile
• Malononitrile
• Acetone cyanohydrin
• Methacrylonitrile and related compounds

Many are industrial solvents or chemical intermediates.

Their major toxicologic importance is that several nitriles can ultimately generate cyanide, producing cellular hypoxia and potentially severe lactic acidosis, neurologic toxicity, cardiovascular collapse, and death.

A distinctive feature is:

Cyanide toxicity may be delayed because some nitriles must first undergo metabolism.

Common Uses and Exposure Settings

Aliphatic nitriles are encountered in production of:

• Plastics
• Synthetic fibers
• Resins
• Rubber and elastomers
• Dyes
• Pharmaceuticals
• Solvents
• Chemical intermediates

Exposure is most often:

• Occupational
• Accidental
• Industrial

Historically, acetonitrile was also present in some consumer solvent products, including certain artificial-nail adhesive removers.

Routes of Exposure

Potential routes include:

• Ingestion
• Inhalation
• Dermal absorption
• Ocular exposure

Some nitriles can be absorbed substantially through intact skin.

Therefore, contaminated clothing and persistent skin contamination can be clinically important.

Mechanism of Toxicity

Toxicity varies among individual nitriles.

For several compounds:

Parent nitrile → hepatic metabolism → cyanide liberation

CYP-mediated metabolism can generate intermediates that ultimately release free cyanide.

Because metabolism takes time:

Exposure → latent period → increasing cyanide production → delayed deterioration

This differs from direct cyanide exposure, where severe effects may occur almost immediately.

Acetonitrile

Acetonitrile is also known as:

• Methyl cyanide
• Ethanitrile
• Cyanomethane

Despite the name “methyl cyanide,” acetonitrile does not necessarily behave like an immediately available dose of free cyanide.

It must undergo metabolic transformation before substantial cyanide is liberated.

This explains why a patient can initially appear well and deteriorate several hours later.

Acetone Cyanohydrin

Acetone cyanohydrin deserves separate attention.

It can decompose to:

• Acetone
• Hydrogen cyanide

Thus, its cyanide hazard is not dependent on exactly the same delayed metabolic pathway as acetonitrile.

It should be regarded as a potentially serious cyanide-releasing chemical exposure.

Acrylonitrile

Acrylonitrile can cause toxicity through more than one mechanism.

Potential effects include:

• Cyanide-related cellular toxicity
• Direct irritation
• Neurologic effects

Chronic occupational exposure is also important because acrylonitrile is recognized as a carcinogenic hazard.

Acute management, however, centers on exposure control, supportive care, and recognition of possible cyanide toxicity.

Cyanide Pathophysiology

Cyanide binds mitochondrial cytochrome c oxidase (Complex IV).

This inhibits oxidative phosphorylation.

Consequently:

Oxygen may reach tissues → cells cannot use it effectively → ATP production fails

This is called histotoxic hypoxia.

Why Lactate Rises

When mitochondrial oxidative metabolism fails:

Pyruvate → lactate

instead of entering normal aerobic metabolism.

Severe cyanide poisoning can therefore produce:

• Markedly elevated lactate
• High-anion-gap metabolic acidosis
• Cardiovascular instability

An otherwise unexplained severe lactic acidosis after nitrile exposure should raise concern for cyanide generation.

Delayed Toxicity

One of the most important features of acetonitrile and some related nitriles is the possibility of a substantial delay between exposure and severe toxicity.

Patients may initially have only:

• Nausea
• Headache
• Mild dizziness
• Mucosal irritation

and later develop:

• Confusion
• Seizures
• Severe lactic acidosis
• Hypotension
• Cardiovascular collapse

Therefore:

Initial wellness does not necessarily exclude dangerous poisoning.

Clinical Features – Mild/Early Exposure

Possible early manifestations include:

• Headache
• Lightheadedness
• Nausea
• Vomiting
• Abdominal discomfort
• Anxiety
• Mucosal irritation
• Eye irritation
• Skin irritation

These findings are nonspecific.

Neurologic Toxicity

Progressive cyanide toxicity can cause:

• Agitation
• Confusion
• Ataxia
• Tremor
• Altered mental status
• Seizures
• Coma

Neurologic deterioration may develop rapidly once systemic cyanide toxicity becomes significant.

Cardiovascular Toxicity

Possible manifestations include:

• Tachycardia
• Hypotension
• Dysrhythmias
• Poor peripheral perfusion
• Shock
• Cardiovascular collapse

Severe hypotension indicates advanced poisoning and requires immediate resuscitation and consideration of cyanide-directed antidotal therapy.

Respiratory Findings

Patients may develop:

• Tachypnea
• Hyperpnea
• Dyspnea
• Chest discomfort

Early hyperventilation may represent compensation for metabolic acidosis.

Advanced poisoning can instead produce:

• CNS respiratory depression
• Respiratory failure

Pulmonary edema has occasionally been described in severe exposures.

Pulse Oximetry Can Be Misleading

Cyanide poisoning primarily prevents cellular oxygen utilization, rather than preventing oxygen from reaching arterial blood.

Therefore:

A normal pulse-oximeter reading does not exclude cyanide poisoning.

Clinical status, lactate, acid–base abnormalities, hemodynamics, and exposure history are more informative.

Skin Color Is Not Diagnostic

The classic description of “cherry-red skin” is unreliable.

It may be:

• Absent
• Difficult to recognize
• Present only very late
• Confounded by other physiologic changes

Therefore:

Do not diagnose or exclude cyanide poisoning based on skin color.

Dermal Exposure

Some nitriles can penetrate skin.

Management includes:

• Removing contaminated clothing
• Preventing secondary contamination of staff
• Prompt washing of exposed skin with water and appropriate cleansing

Persistent contamination should be considered if exposure involved a large amount of liquid chemical.

Ocular Exposure

Splash exposure may cause significant irritation or chemical injury.

Immediate management centers on:

• Prompt irrigation
• Removal of contact lenses when readily possible
• Continued assessment for persistent pain or visual abnormalities

Significant ocular injury requires appropriate ophthalmic evaluation.

Diagnosis

Diagnosis is primarily based on:

• Exposure history
• Clinical syndrome
• Acid–base findings
• Serum lactate
• Hemodynamic status
• Neurologic findings

Do not wait for a cyanide concentration before treating a critically ill patient with a convincing exposure.

Important Laboratory Tests

Useful investigations include:

• Electrolytes
• Bicarbonate
• Anion gap
• Creatinine
• Glucose
• Blood gas
• Lactate

In severe illness also consider:

• ECG
• Continuous cardiac monitoring
• Serial lactate
• Serial blood gases
• Renal and hepatic function
• Other testing directed by coexposures

Lactic Acidosis

A rising lactate is an important clue to clinically significant cyanide toxicity.

However:

Elevated lactate is not specific for cyanide.

Other causes include:

• Shock
• Sepsis
• Seizures
• Carbon monoxide
• Metformin
• Severe hypoxemia
• Other mitochondrial toxins

Interpret lactate in the context of the exposure and clinical syndrome.

Cyanide Levels

Blood cyanide testing has important limitations.

Results are often:

• Not rapidly available
• Technically difficult
• Affected by specimen collection and handling
• Too slow to guide emergency antidotal decisions

Therefore:

Cyanide concentrations may support retrospective confirmation but should not delay treatment.

Historical concentration-to-severity ranges should not be used as rigid bedside treatment thresholds.

Thiocyanate Levels

Cyanide can be converted to thiocyanate, which is subsequently eliminated primarily by the kidneys.

Thiocyanate measurements are generally not useful for immediate diagnosis of acute nitrile poisoning.

They may reflect metabolism or exposure but should not replace clinical assessment.

Arteriovenous Oxygen Difference

Cyanide impairs tissue oxygen extraction, so venous blood can remain unusually oxygenated.

Historically, a reduced arterial–venous oxygen difference was described as a clue.

In practice, this is neither sufficiently convenient nor specific to serve as a primary diagnostic test.

Differential Diagnosis

A patient with altered consciousness and high-anion-gap metabolic acidosis may also have:

• Methanol poisoning
• Ethylene glycol poisoning
• Salicylate poisoning
• Carbon monoxide poisoning
• Metformin-associated lactic acidosis
• Iron poisoning
• Isoniazid toxicity
• Sepsis
• Shock
• Prolonged seizures
• Diabetic or alcoholic ketoacidosis

The exposure history is therefore particularly important.

Initial Management

Priorities are:

• Terminate exposure
• Protect rescuers and healthcare personnel
• Remove contaminated clothing when appropriate
• Decontaminate exposed skin/eyes
• Assess airway and ventilation
• Provide supplemental oxygen when indicated
• Establish cardiovascular monitoring
• Treat seizures and shock
• Recognize emerging cyanide toxicity

Because deterioration may be delayed, continued observation is important after meaningful exposure.

Oxygen

High-concentration oxygen is traditionally used in suspected cyanide poisoning.

Oxygen alone does not directly remove cyanide from cytochrome oxidase, but it supports tissue oxygen delivery and treatment of associated hypoxemia or pulmonary injury.

It should not delay specific antidotal therapy in severe cyanide toxicity.

Modern Cyanide Antidote – Hydroxocobalamin

The older source emphasizes the traditional nitrite–thiosulfate cyanide antidote kit.

Modern practice has changed substantially.

Hydroxocobalamin is now an important first-line antidote for serious cyanide poisoning in many settings.

It binds cyanide to form:

Cyanide + hydroxocobalamin → cyanocobalamin

which can then be eliminated.

Advantages of Hydroxocobalamin

A major advantage is that it does not intentionally create methemoglobinemia.

This is particularly useful when:

• Oxygen delivery is already impaired
• Carbon monoxide exposure is possible
• The patient is critically ill
• The exact exposure is uncertain but cyanide poisoning is strongly suspected

Hydroxocobalamin Adverse Effects

Expected or possible effects include:

• Red discoloration of skin
• Red-colored urine
• Transient blood-pressure elevation
• Laboratory assay interference

The intense red coloration can interfere with some colorimetric laboratory measurements and certain dialysis equipment.

Sodium Thiosulfate

Sodium thiosulfate acts as a sulfur donor, facilitating conversion of cyanide toward thiocyanate.

It may be used:

• As an adjunct to hydroxocobalamin in selected severe poisoning
• In specific cyanide-treatment protocols

Its onset and role differ from hydroxocobalamin.

Nitrite Antidotes – Historical Role

Sodium nitrite produces methemoglobin, which can bind cyanide.

However, methemoglobin cannot carry oxygen normally.

Therefore nitrite therapy can worsen oxygen-delivery problems, particularly in patients with:

• Carbon monoxide exposure
• Significant anemia
• Hypoxemia
• Severe cardiovascular instability

For these reasons, the historical nitrite-based antidote kit is no longer automatically preferred for every cyanide exposure.

Nitrile Poisoning and Antidote Timing

Because cyanide release from acetonitrile can be delayed, antidotal decisions should be based on:

• Exposure severity
• Symptoms
• Lactate
• Acid–base status
• Hemodynamic findings
• Neurologic findings
• Clinical trajectory

Routine prophylactic antidote administration to every asymptomatic nitrile exposure is not necessarily appropriate.

Conversely, a critically ill patient should not wait for laboratory confirmation.

Seizures

Seizures increase:

• Oxygen demand
• Lactate production
• Risk of aspiration
• Secondary neurologic injury

They require prompt conventional seizure management alongside treatment of the underlying cyanide toxicity.

Persistent seizures should raise concern for severe poisoning.

Hypotension and Shock

Management includes:

• Appropriate IV fluid resuscitation
• Vasopressor support when necessary
• Treatment of the underlying cyanide toxicity

The historical routine use of Trendelenburg positioning and central venous pressure targets is outdated.

Modern hemodynamic management is individualized according to perfusion, cardiac function, volume status, and response to treatment.

GI Decontamination – Important Modern Correction

The source recommends ipecac and gastric lavage.

These practices are obsolete for routine nitrile poisoning.

Do not induce vomiting.

Ipecac can:

• Delay definitive treatment
• Increase aspiration risk
• Complicate management

Routine gastric lavage is also not recommended.

Activated Charcoal

Activated charcoal may occasionally be considered after a recent ingestion when:

• The substance is expected to be adsorbed
• The exposure is clinically significant
• The patient presents early
• The airway is safe

However, evidence for benefit in nitrile poisoning is limited.

Charcoal must never delay resuscitation, decontamination, or cyanide-directed therapy.

Delayed Observation

A fixed observation period is not appropriate for every nitrile.

The required duration depends on:

• Specific compound
• Route
• Amount/concentration
• Duration of exposure
• Symptoms
• Laboratory findings
• Expected metabolic delay

Acetonitrile deserves particular caution because significant cyanide toxicity can be delayed for many hours.

Asymptomatic Exposure

An initially asymptomatic patient with a meaningful acetonitrile or other cyanogenic nitrile exposure may still require prolonged clinical observation.

Serial assessment may include:

• Mental status
• Vital signs
• Lactate
• Acid–base status
• Cardiovascular monitoring

The older universal “6-hour versus 24-hour” discharge rules should not be applied mechanically.

Pregnancy

The older statement that acetonitrile is simply a “probable teratogen” is insufficient for clinical management.

Pregnancy does not change the priority of treating serious maternal poisoning.

Severe maternal:

• Hypotension
• Hypoxia
• Acidosis
• Seizures

pose substantial fetal risk.

When clinically significant cyanide toxicity occurs, maternal stabilization and appropriate antidotal treatment take priority.

Historical FDA pregnancy-letter categories are obsolete.

Occupational Exposure

Workplace limits are chemical-specific and can change over time.

Historical OSHA or NIOSH concentration limits should not be memorized as universal current values.

For occupational evaluation, use the current regulatory standard applicable to:

• The specific nitrile
• Country/jurisdiction
• Exposure duration
• Workplace setting

Acrylonitrile and Chronic Exposure

Acute poisoning and chronic occupational risk should be distinguished.

Acrylonitrile has important carcinogenic potential, so chronic occupational exposure requires:

• Exposure prevention
• Industrial hygiene
• Appropriate workplace surveillance

This is separate from emergency treatment of acute cyanide-like toxicity.

Monitoring

After clinically important exposure, monitor as appropriate:

• Airway and ventilation
• Oxygenation
• Heart rate and blood pressure
• ECG
• Mental status
• Seizure activity
• Lactate
• Blood gas
• Anion gap/bicarbonate
• Renal function
• Clinical response to antidotal therapy

Serial trends are often more informative than isolated laboratory values.

Important Modernization of the Older Source

• Aliphatic nitriles contain a –C≡N group, but toxicity varies substantially among individual compounds.
• Acetonitrile and several related nitriles can produce delayed cyanide poisoning after metabolic conversion.
• Acetone cyanohydrin can release cyanide more directly and should be treated as a particularly hazardous cyanide-releasing chemical.
• Cyanide inhibits mitochondrial Complex IV, causing histotoxic hypoxia and severe lactic acidosis.
• Normal pulse oximetry does not exclude cyanide toxicity.
• “Cherry-red skin” is an unreliable finding and should not guide diagnosis.
• Serum lactate is an important severity clue but is not specific for cyanide.
• Cyanide concentrations are usually too slow and unreliable for emergency decision-making.
• Treatment should not wait for a cyanide level in a critically ill patient with a convincing exposure.
• Hydroxocobalamin has largely replaced routine reliance on the traditional nitrite-based cyanide antidote kit in many clinical settings.
• Sodium thiosulfate remains an adjunct in selected cases.
• Nitrite antidotes can impair oxygen carrying capacity by producing methemoglobinemia and require careful selection.
• Ipecac is obsolete and should not be used.
• Routine gastric lavage is not recommended.
• Dermal exposure requires prompt removal of contaminated clothing and skin decontamination.
• Observation duration should be individualized because delayed toxicity varies by nitrile.
• The older routine Trendelenburg/CVP-directed shock strategy is outdated.
• Pregnancy does not justify withholding lifesaving maternal cyanide treatment.
• Historical occupational exposure limits should be checked against current jurisdiction-specific standards rather than memorized from older references.
• Exact antidote doses and occupational concentration limits should follow current poison-center, toxicology, product, and regulatory guidance.

Key Points

• Acetonitrile and some other nitriles → metabolism → cyanide release.
• Cyanide → Complex IV inhibition → failure of oxidative phosphorylation → lactate + cellular energy failure.
• Severe toxicity can be delayed for hours, especially with acetonitrile.
• Watch for altered mental status, seizures, hypotension, rising lactate, and high-anion-gap metabolic acidosis.
• Normal oxygen saturation does not rule out cyanide poisoning.
• Cyanide levels should not delay emergency treatment.
• Hydroxocobalamin is a major modern antidote for serious cyanide toxicity.
• Sodium thiosulfate may provide additional cyanide detoxification in selected cases.
• Remove ongoing dermal contamination promptly because some nitriles are absorbed through skin.
• Do not use ipecac, and do not routinely perform gastric lavage.
• An initially well patient can deteriorate later, so meaningful cyanogenic nitrile exposures require appropriately prolonged observation.

Toxicology – Acetaminophen (Paracetamol): Repeated

Supratherapeutic Ingestion

Core Concept

Repeated supratherapeutic ingestion (RSTI) refers to excessive acetaminophen taken repeatedly over a period of time rather than as one clearly timed acute overdose.

It commonly occurs unintentionally when a person:

• Takes excessive doses for persistent pain or fever
• Uses several acetaminophen-containing products simultaneously
• Misunderstands product concentration or dosing
• Continues treatment longer or more frequently than intended

The major complication is hepatotoxicity from excessive formation of N-acetyl-p-benzoquinone imine (NAPQI).

The specific antidote is N-acetylcysteine (NAC).

RSTI vs Acute Single Ingestion

This distinction is essential.

Acute single ingestion

A large amount is taken at one reasonably well-defined time.

When appropriate, risk can be assessed using an appropriately timed acetaminophen concentration and the Rumack–Matthew nomogram.

Repeated supratherapeutic ingestion

Excessive acetaminophen is taken repeatedly over many hours or days.

In RSTI:

The Rumack–Matthew nomogram must NOT be used.

Instead, management is based on:

• Exposure history
• Serum acetaminophen concentration
• AST and ALT
• INR
• Clinical evidence of hepatic injury
• Risk factors and clinical course

Mechanism of Toxicity

Most therapeutic acetaminophen undergoes:

• Glucuronidation
• Sulfation

A smaller fraction undergoes CYP-mediated metabolism, particularly through CYP2E1, generating:

NAPQI

Normally:

NAPQI + glutathione → nontoxic conjugates

With excessive exposure:

↑ NAPQI + ↓ glutathione → mitochondrial injury → hepatocyte death

The centrilobular region of the liver is particularly vulnerable.

Why Repeated Ingestion Can Be Dangerous

With repeated excessive dosing, the patient may continuously generate NAPQI while hepatic glutathione reserves become progressively depleted.

Unlike a single overdose, there may be:

• No clear starting time
• No single peak acetaminophen concentration
• Ongoing absorption
• Ongoing toxic metabolite formation

Consequently, a relatively modest serum acetaminophen concentration can coexist with significant hepatic injury.

Do Not Rely on a Single “Toxic Dose”

The historical source uses fixed daily thresholds.

Modern assessment is more nuanced.

Risk depends on:

• Total dose
• Dose per unit body weight
• Duration of excessive dosing
• Age
• Nutritional status
• Fasting
• Intercurrent illness
• Hepatic function
• Alcohol exposure
• Timing of presentation

Dose history helps identify patients requiring evaluation, but it does not replace laboratory testing.

Common Causes of RSTI

Typical scenarios include:

• Severe dental pain
• Musculoskeletal pain
• Headache
• Persistent fever
• Viral illness
• Postoperative pain
• Caregiver dosing errors
• Multiple combination cold/flu products
• Simultaneous prescription and OTC acetaminophen products

Patients may genuinely be unaware that several products contain the same active ingredient.

Combination Products

Always check the complete ingredient list.

Acetaminophen may be combined with:

• Opioids
• Antihistamines
• Decongestants
• Caffeine
• Cough suppressants

Clinical findings may therefore reflect both acetaminophen and a coingestant.

Risk Factors

Potential vulnerability may be increased by circumstances associated with reduced glutathione reserves or altered metabolism, including:

• Prolonged fasting
• Malnutrition
• Significant chronic alcohol use
• Severe intercurrent illness
• Low body weight
• Other causes of poor nutritional intake

However, risk factors should not replace objective evaluation.

Alcohol – Important Nuance

The relationship between alcohol and acetaminophen toxicity is complex.

Chronic heavy alcohol use may be associated with:

• CYP2E1 induction
• Malnutrition
• Reduced glutathione reserves

Acute ethanol exposure, however, can transiently compete for CYP2E1.

Therefore:

Alcohol use alone does not determine whether toxicity will occur.

Acetaminophen concentration, liver tests, exposure pattern, and clinical findings remain more important.

Enzyme-Inducing Medications

Older teaching suggested that medications such as carbamazepine or isoniazid automatically produce a major increase in acetaminophen toxicity.

The clinical relationship is less straightforward.

Medication history remains relevant, but treatment decisions should not be based solely on presumed CYP induction.

Clinical Presentation

RSTI can be more difficult to recognize than a single acute overdose because patients often present after hepatic injury has already begun.

Possible early symptoms include:

• Nausea
• Vomiting
• Malaise
• Poor appetite
• Abdominal discomfort
• Right upper quadrant pain

Some patients have few symptoms despite substantial biochemical injury.

Hepatic Injury

Possible findings include:

• Rising AST
• Rising ALT
• Increasing INR
• Right upper quadrant tenderness
• Jaundice

Severe injury can progress to acute liver failure.

Acute Liver Failure

Severe acetaminophen hepatotoxicity may cause:

• Coagulopathy
• Hypoglycemia
• Lactic acidosis
• Hepatic encephalopathy
• Hyperammonemia
• Cerebral edema
• Acute kidney injury
• Hemodynamic instability
• Multiorgan failure

These patients require intensive monitoring and early specialist involvement.

Renal Injury

Acute kidney injury can accompany acetaminophen toxicity and occasionally occurs without proportionate hepatic injury.

Monitor:

• Creatinine
• Electrolytes
• Urine output

Severe renal failure may require renal replacement therapy for standard clinical indications.

Children

Repeated acetaminophen dosing errors can occur when:

• Different liquid concentrations are confused
• Adult formulations are used accidentally
• Multiple caregivers independently administer doses
• Fever persists and doses are given too frequently
• Several combination products are used

Young children may present with nonspecific findings such as:

• Lethargy
• Poor feeding
• Vomiting
• Dehydration

A careful medication history is essential.

Safeguarding Considerations

When the exposure history is inconsistent with the child’s developmental abilities or caregiver explanation, clinicians should consider:

• Medication error
• Unsafe medication storage
• Inadequate supervision
• Nonaccidental administration

This requires careful clinical and safeguarding assessment rather than assuming abuse solely from the child’s age.

Essential Laboratory Evaluation

When clinically significant RSTI is suspected, important tests include:

• Serum acetaminophen concentration
• AST
• ALT
• INR
• Creatinine
• Electrolytes
• Glucose

Additional testing depends on severity.

Serum Acetaminophen Concentration

A serum acetaminophen concentration remains useful in RSTI, but it is interpreted differently from an acute single ingestion.

A detectable concentration may indicate continuing exposure and ongoing risk.

However:

Do not plot it on the Rumack–Matthew nomogram.

A Low Level Does Not Mean Low Risk

In RSTI, substantial hepatic injury can occur when the serum acetaminophen concentration is relatively low.

Why?

Because the patient may have been taking acetaminophen repeatedly for days, and much of the earlier drug has already been metabolized.

Therefore:

Serum concentration must be interpreted together with AST/ALT and the clinical history.

Undetectable Acetaminophen

An undetectable concentration also does not automatically exclude acetaminophen-induced liver injury.

By the time severe hepatotoxicity becomes apparent:

• The last dose may have been many hours earlier.
• Parent acetaminophen may have been cleared.
• Hepatic injury may already be established.

This is particularly important in delayed presentations.

AST and ALT

Aminotransferases are central to assessment.

Significant acetaminophen hepatotoxicity can produce very large elevations.

Serial measurements are more useful than a single isolated result because the trajectory helps establish whether injury is:

• Developing
• Peaking
• Improving

INR

INR is an important marker of hepatic synthetic function in significant acetaminophen-associated liver injury.

A progressively rising INR is concerning.

However, INR should be interpreted with:

• AST/ALT
• Clinical status
• Glucose
• Lactate
• Renal function
• Encephalopathy

No single laboratory measurement defines overall prognosis.

Additional Tests in Severe Toxicity

Depending on the clinical situation, consider:

• Blood gas
• Lactate
• Bilirubin
• Phosphate
• CBC
• Ammonia in patients with encephalopathy
• Additional studies for alternative causes of acute liver failure

Rumack–Matthew Nomogram – Do Not Use

This is one of the highest-yield distinctions.

The nomogram assumes:

• A single ingestion
• A reasonably known ingestion time
• Predictable absorption kinetics

RSTI violates these assumptions.

Therefore:

Repeated ingestion + serum level ≠ nomogram plotting.

N-Acetylcysteine (NAC)

NAC remains the specific antidote.

It:

• Replenishes cysteine for glutathione synthesis
• Enhances detoxification of NAPQI
• Provides antioxidant effects
• Supports mitochondrial function
• May improve hepatic microcirculation in established liver injury

NAC should not be viewed as useful only before hepatotoxicity occurs.

When NAC Is Considered

NAC is appropriate when RSTI is associated with evidence suggesting clinically important acetaminophen exposure or hepatic injury.

Important findings include:

• A clinically meaningful detectable acetaminophen concentration
• Elevated AST or ALT in a compatible exposure
• Evidence of evolving acetaminophen-associated liver injury
• Uncertain exposure with concerning laboratory abnormalities

Current poison-center or medical-toxicology protocols should guide borderline cases.

Do Not Delay NAC in a Sick Patient

If a patient has:

• A convincing history of excessive acetaminophen exposure
• Significant aminotransferase elevation
• Coagulopathy
• Acute liver failure

NAC should not be delayed while waiting for every confirmatory test.

Its safety profile is favorable, and benefit can persist even after hepatic injury has developed.

NAC After Hepatic Injury Has Begun

NAC can improve outcomes even after the window for preventing initial NAPQI injury has passed.

Late benefits are thought to involve:

• Antioxidant activity
• Improved mitochondrial function
• Improved microcirculation
• Support of hepatic recovery

Therefore:

Late presentation is not a reason to withhold NAC.

Duration of NAC – Important Modern Correction

The historical source recommends treatment for a predetermined minimum period.

Modern management increasingly uses clinical and biochemical stopping criteria rather than an arbitrary duration alone.

NAC generally continues while there is evidence of ongoing toxicity, such as:

• Clinically relevant detectable acetaminophen
• Rising or substantially abnormal AST/ALT
• Worsening INR attributable to hepatic injury
• Deteriorating clinical status

Stopping NAC

Treatment may be stopped when appropriate clinical criteria are satisfied, typically including:

• Acetaminophen no longer clinically significant
• Aminotransferases improving or appropriately normal
• Hepatic synthetic function improving
• Patient clinically stable

Severe liver failure may require prolonged NAC despite disappearance of acetaminophen from blood.

Previous NAC Reaction

The older statement that previous anaphylaxis absolutely contraindicates NAC is too restrictive.

IV NAC can cause non-IgE-mediated anaphylactoid reactions, but these are often manageable.

When NAC is strongly indicated, a previous reaction generally warrants:

• Careful monitoring
• Appropriate management of hypersensitivity
• Specialist guidance

rather than automatic withholding of a potentially lifesaving antidote.

Activated Charcoal

Activated charcoal has a much smaller role in RSTI than in a recent single acute ingestion.

It may occasionally be appropriate if a substantial recent dose was taken and significant drug is still expected within the gastrointestinal tract.

However, most patients with RSTI present long after earlier doses have been absorbed.

Therefore:

Routine charcoal is not useful simply because repeated excessive dosing occurred.

Ipecac and Gastric Lavage

Neither has a routine role.

Do not induce vomiting.

Routine gastric lavage is not appropriate for RSTI.

Antiemetics

Vomiting should be managed appropriately, especially when it interferes with:

• Hydration
• Electrolyte correction
• Oral medications
• Antidotal treatment

Modern antiemetic selection should be individualized rather than following the older multidrug regimens automatically.

Coagulopathy

In acute liver failure, INR is both a marker of hepatic synthetic dysfunction and part of prognostic assessment.

Routine administration of plasma solely to normalize an abnormal INR is generally avoided in a patient without clinically important bleeding.

Unnecessary plasma can:

• Cause volume overload
• Cause transfusion reactions
• Obscure the natural INR trend

Blood products are used for appropriate bleeding or procedural indications.

Vitamin K

Vitamin K does not reverse acetaminophen hepatotoxicity.

It may be considered if concomitant vitamin K deficiency is suspected, but severe hepatic synthetic failure will not normalize simply because vitamin K is administered.

Cimetidine

Cimetidine was historically investigated as a way to reduce CYP-mediated NAPQI formation.

It has no established routine role in modern acetaminophen poisoning.

NAC remains the specific antidote.

Acute Liver Failure and Transplant Referral

Patients with severe acetaminophen-induced liver failure should be discussed early with a liver transplant center.

Do not wait until irreversible multiorgan failure develops.

Important prognostic features include:

• Encephalopathy
• INR trajectory
• Arterial pH
• Lactate
• Creatinine
• Hypoglycemia
• Hemodynamic instability
• Overall clinical trajectory

Established systems such as the King’s College criteria may assist assessment, but no single criterion should replace specialist evaluation.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Pregnancy does not change the fundamental indication for NAC.

Maternal hepatic failure poses substantial fetal risk, so:

Treat the pregnant patient promptly when NAC is indicated.

NAC crosses the placenta.

Neonate After Maternal Toxicity

Routine administration of a fixed NAC course to every newborn after maternal acetaminophen poisoning is not a universal modern recommendation.

Neonatal management depends on:

• Maternal exposure
• Timing of poisoning
• Maternal NAC treatment
• Timing of delivery
• Neonatal acetaminophen concentration when relevant
• Neonatal hepatic status

Specialist neonatal/toxicology evaluation is appropriate.

Differential Diagnosis

Other causes of marked hepatic injury include:

• Ischemic hepatitis
• Viral hepatitis
• Autoimmune hepatitis
• Alcohol-associated hepatitis
• Amanita mushroom poisoning
• Valproate toxicity
• Other drug-induced liver injury
• Herbal or plant hepatotoxins

Acetaminophen exposure should nevertheless be considered in otherwise unexplained acute liver failure because the history may initially be incomplete.

Monitoring During Treatment

Depending on severity, follow:

• AST
• ALT
• INR
• Acetaminophen concentration when relevant
• Creatinine
• Electrolytes
• Glucose
• Mental status

In severe cases also monitor:

• Lactate
• Acid–base status
• Phosphate
• Hemodynamics
• Urine output
• Ammonia when clinically relevant

The direction of change is often more useful than one isolated result.

Expected Course

Patients identified and treated before severe liver failure generally have an excellent prognosis.

Even patients with significant hepatotoxicity can recover because the liver has substantial regenerative capacity.

Poor prognostic features include progressive:

• Encephalopathy
• Coagulopathy
• Lactic acidosis
• Renal failure
• Hypoglycemia
• Multiorgan dysfunction

Some patients ultimately require liver transplantation.

Discharge Principles

Medical discharge is appropriate only after clinicians establish that:

• Acetaminophen toxicity is no longer progressing
• Hepatic function is stable or improving
• Renal function is acceptable
• NAC has been appropriately discontinued
• The source of repeated excessive dosing has been addressed
• The patient or caregiver understands safe medication use

Intentional ingestion additionally requires appropriate safety assessment.

Prevention

A major cause of RSTI is accidental duplication.

Patients and caregivers should be taught to:

• Check the active ingredient on every product.
• Recognize that “acetaminophen” and “paracetamol” are the same medication.
• Avoid taking several acetaminophen-containing products simultaneously.
• Use age-appropriate pediatric formulations.
• Measure liquid medications accurately.
• Keep a dosing record when several caregivers are treating a child.
• Follow current product-specific dosing instructions.

Important Modernization of the Older Source

• The preferred term is repeated supratherapeutic ingestion (RSTI) rather than simply “chronic overdose.”
• RSTI does not have the predictable pharmacokinetics of a single acute ingestion.
• Never use the Rumack–Matthew nomogram for RSTI.
• Assessment relies primarily on exposure history, serum acetaminophen, AST/ALT, INR, renal function, and clinical findings.
• A relatively low acetaminophen concentration can coexist with severe hepatic injury.
• An undetectable concentration does not exclude late acetaminophen hepatotoxicity.
• Fixed historical dose thresholds are useful for screening but should not be treated as absolute toxicity boundaries.
• Malnutrition and prolonged fasting can increase vulnerability.
• The relationship between chronic alcohol exposure, CYP induction, and acetaminophen toxicity is more nuanced than older descriptions suggest.
• NAC remains beneficial even after hepatic injury develops.
• Modern NAC treatment uses clinical and laboratory stopping criteria, not simply a fixed minimum duration.
• A previous NAC reaction is not necessarily an absolute contraindication.
• Activated charcoal has only a limited role unless a substantial dose was taken recently.
• Routine plasma administration solely to normalize INR is generally inappropriate without bleeding or another specific indication.
• Cimetidine is not recommended.
• Severe acute liver failure warrants early liver-transplant-center consultation.
• Pregnancy is not a reason to withhold NAC.
• Routine fixed-course neonatal NAC after every maternal overdose is not universally indicated.
• Historical FDA pregnancy categories are obsolete.

Key Points

• RSTI = repeated excessive acetaminophen exposure over time rather than one clearly timed overdose.
• Do not use the Rumack–Matthew nomogram.
• Toxicity results from NAPQI formation + inadequate glutathione detoxification + mitochondrial hepatocyte injury.
• Check acetaminophen concentration + AST/ALT + INR + renal function.
• A low or undetectable acetaminophen concentration does not exclude established hepatotoxicity.
• NAC is the specific antidote and remains useful even after liver injury begins.
• Continue NAC until appropriate clinical and biochemical stopping criteria are met.
• Persistent vomiting, malnutrition, fasting, and unrecognized duplicate acetaminophen products are important clinical clues.
• Progressive encephalopathy, coagulopathy, acidosis, renal failure, or multiorgan dysfunction requires intensive management and early transplant-center involvement.
• Prevent recurrence by identifying all acetaminophen/paracetamol-containing products the patient has been using.

Toxicology – Acetaminophen (Paracetamol): Acute Single Ingestion

Core Concept

Acetaminophen (paracetamol) is a widely used analgesic and antipyretic. Acute overdose can cause severe centrilobular hepatic necrosis and acute liver failure, even though patients may initially appear well.

The specific antidote is N-acetylcysteine (NAC).

The major principles are:

• Obtain an appropriately timed serum acetaminophen concentration.
• Use the Rumack–Matthew nomogram only when its assumptions are satisfied.
• Start NAC promptly when indicated.
• Do not delay NAC when waiting for testing would push treatment beyond the optimal early window.
• Continue or stop NAC according to clinical and laboratory endpoints rather than an inflexible historical course length.

Common Sources of Exposure

Acetaminophen is found in:

• Single-ingredient analgesics
• Cold and flu products
• Sleep preparations
• Prescription combination analgesics
• Pediatric liquids
• Extended-release preparations

Combination products may also contain:

• Opioids
• Antihistamines
• Decongestants
• Caffeine
• Other medications

Therefore, the exact product and all active ingredients should be identified whenever possible.

Mechanism of Toxicity

At therapeutic exposure, most acetaminophen undergoes hepatic:

• Glucuronidation
• Sulfation

These pathways generate relatively nontoxic metabolites.

A smaller fraction undergoes CYP-mediated oxidation, particularly involving CYP2E1, producing:

N-acetyl-p-benzoquinone imine (NAPQI)

NAPQI is a highly reactive toxic metabolite.

Role of Glutathione

Normally:

Acetaminophen → NAPQI → glutathione conjugation → nontoxic metabolites

After sufficiently large exposure:

• Normal conjugation pathways become overwhelmed.
• NAPQI production becomes clinically important.
• Hepatic glutathione becomes depleted.
• Unneutralized NAPQI binds cellular proteins.

This initiates:

• Oxidative stress
• Mitochondrial dysfunction
• Hepatocyte injury
• Centrilobular hepatic necrosis

Why NAC Works

NAC provides cysteine needed for glutathione synthesis and helps restore the liver’s ability to detoxify NAPQI.

Its benefits also extend beyond simple glutathione replacement, particularly in established liver injury, where antioxidant, mitochondrial, and microcirculatory effects may contribute.

Therefore:

NAC remains beneficial even when treatment begins after the ideal early period.

Risk Assessment

A reported dose is useful for deciding who requires evaluation, but serum acetaminophen concentration is more important for definitive risk assessment after a known-time acute ingestion.

Do not base treatment solely on the patient’s estimated number of tablets.

Histories may be inaccurate because of:

• Intentional under-reporting
• Uncertainty about tablet strength
• Combination products
• Incorrect timing
• Vomiting
• Delayed absorption

Clinical Course

Acetaminophen poisoning is classically described in stages, although individual patients do not always follow them precisely.

Early Phase – First 24 Hours

Patients may have:

• Nausea
• Vomiting
• Diaphoresis
• Pallor
• Malaise

But many patients are:

Completely asymptomatic.

This is one of the most important pitfalls in acetaminophen poisoning.

A well-appearing patient shortly after overdose can still develop severe hepatotoxicity.

Developing Hepatic Injury

Over approximately the next 1–3 days, patients may develop:

• Right upper quadrant discomfort
• Increasing AST and ALT
• Increasing INR
• Nausea and vomiting
• Hepatic tenderness

Laboratory abnormalities may become dramatic even while some initial GI symptoms improve.

Severe Toxicity

Severe poisoning can progress to acute liver failure with:

• Coagulopathy
• Hypoglycemia
• Lactic acidosis
• Encephalopathy
• Cerebral edema
• Hyperammonemia
• Acute kidney injury
• Multiorgan failure
• Death

Maximum hepatic injury often becomes evident several days after ingestion.

Recovery

Patients who survive the critical period may undergo substantial hepatic regeneration.

Recovery can be complete because the liver has considerable regenerative capacity.

Some patients with fulminant failure, however, require liver transplantation.

Serum Acetaminophen Concentration

For a single acute ingestion at a known time, obtain a serum acetaminophen concentration at:

4 hours after ingestion or as soon as possible thereafter.

A concentration obtained substantially before 4 hours cannot reliably exclude toxicity because absorption may still be occurring.

Rumack–Matthew Nomogram

The Rumack–Matthew nomogram relates:

Serum acetaminophen concentration ↔ time since ingestion

to estimate hepatotoxicity risk after a single acute ingestion.

In many current protocols, the treatment line begins at approximately 150 µg/mL at 4 hours and declines with time.

Country-specific protocols may differ, so the applicable local treatment line should be used.

When the Nomogram Is Valid

The nomogram is appropriate when:

• There was a single acute ingestion.
• The time of ingestion is reasonably reliable.
• The concentration was obtained within the validated post-ingestion interval.
• There is not already an alternative pattern such as repeated supratherapeutic ingestion.

When the Nomogram Is NOT Valid

Do not use it for:

• Unknown ingestion time
• Repeated supratherapeutic ingestion
• Staggered ingestion over a prolonged period
• Chronic excessive use
• Patients already presenting with established acetaminophen-associated liver injury

These situations require a different assessment using acetaminophen concentration, hepatic tests, history, and clinical findings.

Extended-Release Acetaminophen

Extended-release preparations can produce delayed or prolonged absorption.

A single early concentration below the treatment line may therefore be insufficient in selected cases.

Serial concentrations may be needed, especially when:

• Extended-release acetaminophen was taken
• The initial concentration is detectable but below the treatment line
• Absorption appears delayed

Current poison-center or toxicology guidance should determine the repeat-testing strategy.

Coingestants and Delayed Absorption

Delayed acetaminophen absorption can also occur when coingestants slow gastric emptying, particularly:

• Opioids
• Antimuscarinic drugs

Large tablet burdens or pharmacobezoar formation can also produce unusual kinetics.

A concentration that rises unexpectedly should prompt reassessment rather than blind reliance on the first value.

When to Start NAC Before the Level Returns

NAC is most effective when started early.

If a potentially toxic acute ingestion occurred and the acetaminophen result will not be available before approximately 8 hours after ingestion, NAC should generally be started empirically while awaiting the result.

Treatment can later be reassessed once reliable laboratory information is available.

Why the First 8 Hours Matter

When NAC is initiated within roughly the first 8 hours after an acute overdose, protection against serious hepatotoxicity is excellent.

However:

8 hours is not a cutoff after which NAC becomes useless.

Late treatment can still improve outcomes and should not be withheld when toxicity is suspected or established.

Unknown Time of Ingestion

If the ingestion time cannot be established, the Rumack–Matthew nomogram cannot be interpreted reliably.

Evaluation generally includes:

• Serum acetaminophen concentration
• AST
• ALT
• INR
• Renal function
• Clinical assessment

A measurable acetaminophen concentration in an appropriate overdose context or evidence of hepatic injury may justify NAC.

Late Presentation

Patients presenting after the standard nomogram window require assessment for established injury rather than simple plotting.

Important tests include:

• Acetaminophen concentration
• AST/ALT
• INR
• Creatinine
• Glucose
• Electrolytes
• Acid–base status in severe illness

NAC should be given when acetaminophen-associated hepatic injury is suspected, even if the serum acetaminophen concentration has already fallen substantially or become undetectable.

An Undetectable Level Does Not Always Exclude Acetaminophen Toxicity

This is especially important in delayed presentation.

By the time acute liver failure develops, the parent acetaminophen may already have been cleared.

Therefore:

Undetectable acetaminophen + marked compatible hepatotoxicity ≠ exclusion of acetaminophen poisoning.

History and biochemical pattern remain important.

Liver Tests

Monitor:

• AST
• ALT
• INR
• Bilirubin

AST and ALT may become extremely elevated in severe acetaminophen hepatotoxicity.

However, the older statement that PT prolongation is always the earliest manifestation should not be treated as a universal rule.

The pattern and trajectory of multiple markers are more informative.

Renal Injury

Acute kidney injury can accompany severe acetaminophen poisoning.

Mechanisms may include:

• Direct nephrotoxicity
• Acute tubular injury
• Hypoperfusion
• Multiorgan failure

Importantly, renal injury can occasionally occur even without dramatic hepatic failure.

Monitor:

• Creatinine
• Urine output
• Electrolytes

Metabolic Acidosis

A massive acute ingestion can occasionally produce early high-anion-gap metabolic acidosis and elevated lactate, sometimes before classic hepatic failure develops.

Later acidosis may result from:

• Liver failure
• Shock
• Renal failure
• Impaired lactate clearance

Other causes of metabolic acidosis must still be investigated.

Massive Acetaminophen Poisoning

Exceptionally large acute exposures can present differently from typical poisoning.

Possible early manifestations include:

• Altered mental status
• Severe metabolic acidosis
• Markedly elevated lactate
• Hemodynamic instability

These cases warrant immediate medical-toxicology/poison-center consultation.

Selected extraordinarily severe cases may require hemodialysis in addition to NAC, particularly when early mitochondrial toxicity is profound.

Hemodialysis

Most acetaminophen poisonings do not require dialysis.

Dialysis is reserved for exceptional severe poisoning.

Because NAC can also be removed during dialysis, antidotal therapy requires specialist-directed adjustment when extracorporeal treatment is used.

Activated Charcoal

Activated charcoal may be considered after a substantial recent ingestion when:

• The toxin is still likely to be in the gastrointestinal tract.
• The patient can safely receive charcoal.
• The airway is adequately protected.

Its usefulness may extend beyond a rigid 1-hour cutoff in selected large, extended-release, or delayed-absorption ingestions.

Charcoal and NAC

Activated charcoal can adsorb orally administered NAC to some degree, but this interaction does not justify withholding indicated GI decontamination or antidotal therapy.

Current treatment strategy should account for:

• NAC route
• Timing
• Clinical circumstances

Ipecac – Obsolete

The source recommends inducing vomiting with ipecac.

This is no longer recommended.

Ipecac:

• Does not improve clinical outcomes
• Can delay antidotal therapy
• Causes persistent vomiting
• Increases aspiration concerns

It has no routine role in modern acetaminophen overdose management.

Gastric Lavage

Routine gastric lavage is also obsolete.

It is not standard treatment for acetaminophen poisoning and is reserved, if ever considered, for extraordinary circumstances after specialist consultation.

Activated charcoal is the preferred gastrointestinal decontamination method when decontamination is appropriate.

N-Acetylcysteine

NAC is highly effective and should be used when:

• The appropriately timed acetaminophen concentration reaches or exceeds the applicable treatment line.
• A potentially toxic ingestion occurred and laboratory results will be significantly delayed.
• The time of ingestion is unknown and findings suggest clinically important exposure.
• Acetaminophen-associated hepatic injury is present or strongly suspected.
• Other high-risk circumstances warrant treatment based on toxicology guidance.

Oral vs Intravenous NAC

Both routes can be effective.

IV NAC

Often preferred when there is:

• Persistent vomiting
• Altered mental status
• Acute liver failure
• Inability to tolerate oral treatment
• Need for controlled hospital administration

Oral NAC

Can also be effective when appropriately administered and tolerated.

Modern practice commonly uses IV NAC in hospital settings.

Important Correction – Never Inject the Oral Formulation

The historical source discusses administering oral NAC formulation intravenously.

That is not appropriate modern practice.

Only a formulation specifically manufactured and approved for intravenous administration should be given IV.

Improvised IV administration of an oral formulation should not be performed.

Duration of NAC Therapy

Historical protocols used fixed treatment durations.

Modern practice increasingly emphasizes clinical stopping criteria.

NAC should generally continue if there is:

• Detectable clinically relevant acetaminophen
• Rising or persistently abnormal aminotransferases
• Worsening hepatic function
• Significant coagulopathy attributable to hepatic injury
• Other evidence of ongoing toxicity

Treatment can be stopped when appropriate biochemical and clinical recovery criteria are satisfied.

Do Not Stop NAC Solely Because the Clock Ran Out

A patient with ongoing hepatic injury should not have NAC discontinued merely because a standard protocol duration has been completed.

Conversely, some patients may satisfy validated stopping criteria without needing unnecessarily prolonged treatment.

IV NAC Reactions

IV NAC can cause non-IgE-mediated anaphylactoid reactions.

Possible findings include:

• Flushing
• Pruritus
• Urticaria
• Angioedema
• Bronchospasm
• Hypotension

These reactions are often manageable.

Previous NAC Reaction Is Not Usually an Absolute Contraindication

The older statement that previous anaphylaxis to NAC automatically precludes future use is too restrictive.

When NAC is lifesaving, prior reaction requires:

• Careful risk assessment
• Appropriate monitoring
• Modification of administration when appropriate
• Treatment of recurrent hypersensitivity if it occurs

A prior reaction does not automatically eliminate NAC as an option.

Pregnancy

The historical FDA pregnancy letter category is obsolete.

Pregnant patients should generally receive NAC using the same toxicologic indications as nonpregnant patients.

Maternal stabilization and prevention of maternal liver failure are central to fetal protection.

NAC crosses the placenta.

Neonate After Maternal Overdose

The source recommends automatically giving every infant born to a mother with acetaminophen toxicity a fixed NAC course.

This is not a universal modern rule.

Neonatal evaluation and treatment depend on:

• Timing and severity of maternal poisoning
• Maternal treatment
• Timing of delivery
• Neonatal acetaminophen exposure
• Neonatal hepatic findings
• Specialist assessment

Delivery should not be induced solely as a method of treating maternal acetaminophen poisoning.

Alcohol Use – Important Nuance

Chronic alcohol use can contribute to:

• Malnutrition
• Reduced glutathione reserves
• Altered CYP2E1 activity

However, alcohol history alone does not replace standard risk assessment.

Acute ethanol co-ingestion can transiently compete for CYP2E1, while chronic alcohol-associated nutritional deficiency may increase vulnerability in certain circumstances.

Do not withhold or alter indicated NAC simply because alcohol was involved.

Malnutrition

Malnutrition and prolonged fasting may reduce hepatic glutathione availability.

These factors become particularly relevant in:

• Repeated supratherapeutic ingestion
• Delayed presentation
• Patients with established liver injury

They do not eliminate the need for standard concentration-based assessment after a straightforward known-time single acute ingestion.

Enzyme-Inducing Drugs

Older sources sometimes strongly emphasized CYP-inducing medications as automatically increasing acute acetaminophen toxicity.

The clinical importance is more nuanced than previously suggested.

Medication history remains relevant, but standard acute risk assessment should not be replaced by assumptions based solely on enzyme induction.

Acute Liver Failure

Severe acetaminophen toxicity can cause:

• Encephalopathy
• Coagulopathy
• Hypoglycemia
• Lactic acidosis
• Hyperammonemia
• Cerebral edema
• Renal failure
• Multiorgan dysfunction

These patients require intensive care and early involvement of a liver transplant center.

Transplant Assessment

The source lists older fixed prognostic criteria.

Modern transplant decisions use the complete clinical picture and may incorporate established systems such as King’s College criteria, along with:

• Lactate
• Arterial pH
• INR
• Creatinine
• Encephalopathy
• Hemodynamic status
• Clinical trajectory

No single laboratory value should be used in isolation.

Early referral is preferable to waiting for irreversible deterioration.

Coagulopathy and Blood Products

An elevated INR in acetaminophen-associated liver failure is an important marker of hepatic dysfunction.

Routine correction of an abnormal INR with plasma solely to normalize the laboratory value is generally avoided when there is no clinically important bleeding.

Unnecessary plasma can:

• Cause volume overload
• Produce transfusion reactions
• Obscure INR trends used to assess hepatic function

Blood products are reserved for appropriate clinical indications such as significant bleeding or selected invasive procedures.

Vitamin K

Vitamin K does not correct the fundamental loss of hepatic synthetic function in severe acetaminophen-induced liver failure.

It may be appropriate if concomitant vitamin K deficiency is suspected, but it is not an antidote for acetaminophen hepatotoxicity.

Monitoring During NAC

Important serial assessments include:

• Acetaminophen concentration when relevant
• AST and ALT
• INR
• Creatinine
• Electrolytes
• Glucose

In severe toxicity also consider:

• Blood gas
• Lactate
• Phosphate
• Mental status
• Ammonia in appropriate acute liver failure assessment

Serial Acetaminophen Levels – Modern Correction

The older statement that repeated acetaminophen levels are essentially never useful after NAC starts is too broad.

Repeat concentrations can be important when:

• Extended-release preparations were ingested
• Delayed absorption is suspected
• A large ingestion occurred
• Concentrations remain detectable
• Treatment stopping criteria are being assessed
• The concentration unexpectedly rises
• Dialysis is being considered or performed

Differential Diagnosis of Severe Hepatic Injury

Other causes include:

• Viral hepatitis
• Ischemic hepatitis
• Autoimmune hepatitis
• Amanita mushroom poisoning
• Valproate toxicity
• Certain herbal or plant toxins
• Other drug-induced liver injury

However, acetaminophen should remain high in the differential for otherwise unexplained acute liver failure.

Psychiatric and Safety Assessment

When overdose was intentional, medical stabilization should be followed by an appropriate mental-health and safety evaluation.

This assessment should not delay emergency toxicologic treatment.

Discharge Principles

A patient with a straightforward known-time acute ingestion may be medically cleared when:

• Appropriate acetaminophen testing excludes a toxic exposure, or indicated treatment has been completed
• There is no evidence of evolving hepatic or renal injury
• Clinical status is stable
• Delayed absorption is not a concern
• Coingestants have been appropriately addressed
• Appropriate safety assessment has been completed when the ingestion was intentional

Patients with hepatic injury require continued monitoring until recovery is clearly established.

Prevention

Unintentional overdose frequently occurs because patients unknowingly take multiple acetaminophen-containing products simultaneously.

Education should emphasize:

• Check active ingredients.
• Avoid duplicating acetaminophen-containing medications.
• Use age-appropriate pediatric formulations.
• Measure pediatric liquid medications accurately.
• Follow current product-specific maximum daily dosing instructions.

Important Modernization of the Older Source

• Acetaminophen toxicity results primarily from excessive formation of NAPQI, glutathione depletion, mitochondrial injury, and hepatocellular necrosis.
• A patient can appear completely well during the early phase of a potentially fatal overdose.
• For a known-time single acute ingestion, obtain the acetaminophen concentration at 4 hours or later and apply the appropriate Rumack–Matthew treatment line.
• A level obtained too early cannot reliably exclude toxicity.
• The Rumack–Matthew nomogram does not apply to unknown-time, repeated, staggered, or chronic excessive ingestion.
• Extended-release preparations and drugs that delay gastric emptying may require repeat concentrations.
• Start NAC empirically if waiting for the concentration would significantly delay treatment beyond the optimal early window.
• NAC remains beneficial after 8 hours and even after hepatic injury has developed.
• An undetectable acetaminophen concentration in a late presenter does not exclude acetaminophen-induced liver failure.
• Modern NAC treatment should incorporate clinical stopping criteria, rather than blindly stopping after a fixed duration.
• Repeat acetaminophen concentrations remain useful in selected patients despite the older source’s contrary statement.
• Activated charcoal may be useful after selected recent substantial ingestions.
• Ipecac is obsolete, and routine gastric lavage is not recommended.
• Never administer an oral NAC preparation intravenously.
• Previous NAC hypersensitivity is not automatically an absolute contraindication when antidotal therapy is required.
• Massive acetaminophen poisoning can cause early lactic acidosis, altered consciousness, and mitochondrial dysfunction; dialysis is considered only in exceptional severe cases.
• 4F-PCC/FFP or vitamin K should not routinely be used merely to normalize INR in acetaminophen-associated liver failure.
• Severe acute liver failure warrants early transplant-center involvement.
• Pregnancy is not a reason to withhold NAC.
• Historical FDA pregnancy categories are obsolete.
• Exact NAC dosing should follow current product, poison-center, or medical-toxicology protocols.

Key Points

• Acetaminophen → CYP metabolism → NAPQI → glutathione depletion → hepatic injury.
• NAC replenishes glutathione-related defenses and remains the specific antidote.
• Early absence of symptoms does not exclude severe poisoning.
• Known-time single acute ingestion → ≥4-hour acetaminophen concentration → Rumack–Matthew nomogram.
• Do not use the nomogram for unknown-time, repeated, staggered, or chronic exposures.
• When waiting for testing would substantially delay therapy, start NAC first and reassess later.
• NAC is most protective when given early but can remain lifesaving in late toxicity.
• Extended-release products or delayed gastric emptying can produce delayed concentration peaks.
• Massive poisoning may cause early metabolic acidosis and altered mental status before classic hepatic failure.
• Continue NAC when acetaminophen remains clinically relevant or hepatic injury is still evolving.
• Ipecac and routine gastric lavage have no role in modern routine management.
• Acute liver failure requires intensive monitoring and early transplant-center consultation.